Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 911 articles:
HTML format
Text format



Single Articles


    April 2020
  1. PAN L, Chen X, Fu S, Yu W, et al
    LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05613.
    PubMed     Text format     Abstract available


  2. SUNDELIN EIO, Al-Suliman N, Vahl P, Vendelbo M, et al
    Metformin is distributed to tumor tissue in breast cancer patients in vivo: A (11)C-metformin PET/CT study.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05621.
    PubMed     Text format     Abstract available


  3. DENYS H, Martinez-Mena CL, Martens MT, D'Hondt RG, et al
    Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Breast Cancer Res Treat. 2020 Apr 2. pii: 10.1007/s10549-020-05604.
    PubMed     Text format     Abstract available


  4. LEI YY, Ho SC, Cheng A, Kwok C, et al
    The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients.
    Breast Cancer Res Treat. 2020 Apr 1. pii: 10.1007/s10549-020-05616.
    PubMed     Text format     Abstract available


    March 2020
  5. GONG IY, Yan AT, Earle CC, Trudeau ME, et al
    Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05614.
    PubMed     Text format     Abstract available


  6. VRIENS IJH, Ter Welle-Butalid EM, de Boer M, de Die-Smulders CEM, et al
    Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05598.
    PubMed     Text format     Abstract available


  7. BHATTACHARJEE A, Rajendra J, Dikshit R, Dutt S, et al
    HER2 borderline is a negative prognostic factor for primary malignant breast cancer.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05608.
    PubMed     Text format     Abstract available


  8. BRANDBERG Y, Johansson H, Hellstrom M, Gnant M, et al
    Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.
    Breast Cancer Res Treat. 2020 Mar 31. pii: 10.1007/s10549-020-05602.
    PubMed     Text format     Abstract available


  9. JOBSEN JJ, Struikmans H, van der Palen J, Siemerink E, et al
    The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer.
    Breast Cancer Res Treat. 2020 Mar 30. pii: 10.1007/s10549-020-05610.
    PubMed     Text format     Abstract available


  10. EL ANSARI R, Alfarsi L, Craze ML, Masisi BK, et al
    The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
    Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05586.
    PubMed     Text format     Abstract available


  11. GENNARI A, Foca F, Zamarchi R, Rocca A, et al
    Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Breast Cancer Res Treat. 2020 Mar 21. pii: 10.1007/s10549-020-05596.
    PubMed     Text format     Abstract available


  12. VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
    Behavior of metastatic breast cancer according to subtype.
    Breast Cancer Res Treat. 2020 Mar 19. pii: 10.1007/s10549-020-05597.
    PubMed     Text format     Abstract available


  13. PANZIRONI G, Moffa G, Galati F, Marzocca F, et al
    Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner.
    Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05592.
    PubMed     Text format     Abstract available


  14. HASSETT MJ, Li H, Burstein HJ, Punglia RS, et al
    Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Breast Cancer Res Treat. 2020 Mar 17. pii: 10.1007/s10549-020-05587.
    PubMed     Text format     Abstract available


  15. SIMONS JM, Koppert LB, Luiten EJT, van der Pol CC, et al
    De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05589.
    PubMed     Text format     Abstract available


  16. GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
    Correction to: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
    Breast Cancer Res Treat. 2020 Mar 16. pii: 10.1007/s10549-020-05594.
    PubMed     Text format     Abstract available


  17. MA G, Zhang B, Xu J
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05593.
    PubMed     Text format    


  18. YUAN C, Xie Z, Bian J, Huo J, et al
    Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
    Breast Cancer Res Treat. 2020 Mar 14. pii: 10.1007/s10549-020-05591.
    PubMed     Text format     Abstract available


  19. CROLLEY VE, Marashi H, Rawther S, Sirohi B, et al
    The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
    Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05578.
    PubMed     Text format     Abstract available


  20. ISHIGURO H, Masuda N, Sato N, Higaki K, et al
    A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
    Breast Cancer Res Treat. 2020 Mar 13. pii: 10.1007/s10549-020-05590.
    PubMed     Text format     Abstract available


  21. O'SULLIVAN CC, Irshad S, Wang Z, Tang Z, et al
    Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period.
    Breast Cancer Res Treat. 2020 Mar 11. pii: 10.1007/s10549-020-05585.
    PubMed     Text format     Abstract available


  22. IWASE M, Ando M, Aogi K, Aruga T, et al
    Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Mar 5. pii: 10.1007/s10549-020-05580.
    PubMed     Text format     Abstract available


  23. ANDREANO KJ, Wardell SE, Baker JG, Desautels TK, et al
    G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Breast Cancer Res Treat. 2020 Mar 4. pii: 10.1007/s10549-020-05575.
    PubMed     Text format     Abstract available


  24. TAYLOR LJ, Steiman JS, Anderson B, Schumacher JR, et al
    Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care?
    Breast Cancer Res Treat. 2020 Mar 3. pii: 10.1007/s10549-020-05579.
    PubMed     Text format     Abstract available


  25. VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
    Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05567.
    PubMed     Text format     Abstract available


  26. MASUDA T, Fujimoto H, Teranaka R, Kuroda M, et al
    Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Mar 2. pii: 10.1007/s10549-020-05581.
    PubMed     Text format     Abstract available


    February 2020
  27. JEON YW, Bang HW, Suh YJ, Kim G, et al
    The long-term effect of age on cardiovascular disease in patients with breast cancer who received chemotherapy.
    Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05568.
    PubMed     Text format     Abstract available


  28. PARACHA N, Reyes A, Dieras V, Krop I, et al
    Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analys
    Breast Cancer Res Treat. 2020 Feb 25. pii: 10.1007/s10549-020-05577.
    PubMed     Text format     Abstract available


  29. ROJAS-LIMA E, Gamboa-Loira B, Cebrian ME, Rothenberg SJ, et al
    A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women.
    Breast Cancer Res Treat. 2020 Feb 22. pii: 10.1007/s10549-020-05562.
    PubMed     Text format     Abstract available


  30. LAMBERT-COTE L, Bouhnik AD, Bendiane MK, Berenger C, et al
    Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Breast Cancer Res Treat. 2020 Feb 21. pii: 10.1007/s10549-020-05549.
    PubMed     Text format     Abstract available


  31. PAN K, Ray RM, Cauley JA, Shadyab AH, et al
    Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05576.
    PubMed     Text format     Abstract available


  32. KIM M, Kim H, Ahn SH, Tabatabaie V, et al
    Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients.
    Breast Cancer Res Treat. 2020 Feb 19. pii: 10.1007/s10549-020-05566.
    PubMed     Text format     Abstract available


  33. CHEN L, Fu F, Huang M, Lv J, et al
    The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
    Breast Cancer Res Treat. 2020 Feb 18. pii: 10.1007/s10549-020-05573.
    PubMed     Text format     Abstract available


  34. GONZALEZ TL, Hancock M, Sun S, Gersch CL, et al
    Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer.
    Breast Cancer Res Treat. 2020 Feb 17. pii: 10.1007/s10549-020-05564.
    PubMed     Text format     Abstract available


  35. YUNG R, Ray RM, Roth J, Johnson L, et al
    The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative.
    Breast Cancer Res Treat. 2020 Feb 15. pii: 10.1007/s10549-020-05572.
    PubMed     Text format     Abstract available


  36. CORONA SP, Bortul M, Scomersi S, Bigal C, et al
    Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05565.
    PubMed     Text format     Abstract available


  37. ZHANG L, Hsieh MC, Petkov V, Yu Q, et al
    Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
    Breast Cancer Res Treat. 2020 Feb 14. pii: 10.1007/s10549-020-05557.
    PubMed     Text format     Abstract available


  38. CHEN Z, Xu L, Shi W, Zeng F, et al
    Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017.
    Breast Cancer Res Treat. 2020 Feb 13. pii: 10.1007/s10549-020-05561.
    PubMed     Text format     Abstract available


  39. RYPENS C, Marsan M, Van Berckelaer C, Billiet C, et al
    Inflammatory breast cancer cells are characterized by abrogated TGFbeta1-dependent cell motility and SMAD3 activity.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05571.
    PubMed     Text format     Abstract available


  40. RACHNER TD, Gobel A, Hoffmann O, Erdmann K, et al
    High serum levels of periostin are associated with a poor survival in breast cancer.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05570.
    PubMed     Text format     Abstract available


  41. SARMIENTO S, McColl M, Musavi L, Gani F, et al
    Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05556.
    PubMed     Text format     Abstract available


  42. SORSCHER S, Ansley K, Delaney SD, Ramkissoon S, et al
    The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05569.
    PubMed     Text format     Abstract available


  43. SUN X, Wang XE, Zhang ZP, Shi ZQ, et al
    Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05559.
    PubMed     Text format     Abstract available


  44. YU M, Chen Y, Wang Z, Ding X, et al
    pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05560.
    PubMed     Text format     Abstract available


  45. MILLS MN, Figura NB, Arrington JA, Yu HM, et al
    Management of brain metastases in breast cancer: a review of current practices and emerging treatments.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05552.
    PubMed     Text format     Abstract available


  46. GUO S, Zhang C, Mottamal M, Hossain A, et al
    GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05558.
    PubMed     Text format     Abstract available


  47. JOOB B, Wiwanitkit V
    CYP24A1 polymorphisms and breast cancer risk.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-020-05553.
    PubMed     Text format    



  48. UK Interdisciplinary Breast Cancer Symposium 2020.
    Breast Cancer Res Treat. 2020 Feb 6. pii: 10.1007/s10549-019-05514.
    PubMed     Text format    


  49. PAREKH VS, Jacobs MA
    Multiparametric radiomics methods for breast cancer tissue characterization using radiological imaging.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05533.
    PubMed     Text format     Abstract available


  50. KIM HS, Yoo TK, Park WC, Chae BJ, et al
    The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05550.
    PubMed     Text format     Abstract available


  51. ZHU J, Wang F, Shi L, Cai H, et al
    Accelerated aging in breast cancer survivors and its association with mortality and cancer recurrence.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05541.
    PubMed     Text format     Abstract available


  52. SHIBAYAMA T, Low SK, Ono M, Kobayashi T, et al
    Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-019-05512.
    PubMed     Text format     Abstract available


  53. DICORPO D, Tiwari A, Tang R, Griffin M, et al
    The role of Micro-CT in imaging breast cancer specimens.
    Breast Cancer Res Treat. 2020 Feb 4. pii: 10.1007/s10549-020-05547.
    PubMed     Text format     Abstract available


  54. LI M, Xiong Y, Liao C, He Y, et al
    Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2020 Feb 1. pii: 10.1007/s10549-020-05551.
    PubMed     Text format     Abstract available


  55. ZDRAVKOVIC D, Granic M, Crnokrak B
    Proper treatment of breast angiosarcoma-mastectomy or breast conserving surgery?
    Breast Cancer Res Treat. 2020;179:765.
    PubMed     Text format    


  56. ALTUNDAG K
    Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?
    Breast Cancer Res Treat. 2020;179:763.
    PubMed     Text format    


    January 2020
  57. LINNENBRINGER E, Geronimus AT, Davis KL, Bound J, et al
    Associations between breast cancer subtype and neighborhood socioeconomic and racial composition among Black and White women.
    Breast Cancer Res Treat. 2020 Jan 30. pii: 10.1007/s10549-020-05545.
    PubMed     Text format     Abstract available


  58. QIAN XL, Xu P, Zhang YQ, Song YM, et al
    Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jan 29. pii: 10.1007/s10549-020-05540.
    PubMed     Text format     Abstract available


  59. RAINVILLE I, Hatcher S, Rosenthal E, Larson K, et al
    High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Breast Cancer Res Treat. 2020 Jan 28. pii: 10.1007/s10549-020-05543.
    PubMed     Text format     Abstract available


  60. ROSE M, Svensson H, Handler J, Hoyer U, et al
    Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05544.
    PubMed     Text format     Abstract available


  61. DE BONIFACE J, Ahlgren J, Andersson Y, Bergkvist L, et al
    The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05537.
    PubMed     Text format     Abstract available


  62. KANAI A, McNamara KM, Iwabuchi E, Miki Y, et al
    Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
    Breast Cancer Res Treat. 2020 Jan 27. pii: 10.1007/s10549-020-05523.
    PubMed     Text format     Abstract available


  63. MOUSLIM MC, Johnson RM, Dean LT
    Healthcare system distrust and the breast cancer continuum of care.
    Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05538.
    PubMed     Text format     Abstract available


  64. ZENG F, Heng J, Guo X, Wang Y, et al
    The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
    Breast Cancer Res Treat. 2020 Jan 25. pii: 10.1007/s10549-020-05536.
    PubMed     Text format     Abstract available


  65. PLICHTA JK, Thomas SM, Vernon R, Fayanju OM, et al
    Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.
    Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05542.
    PubMed     Text format     Abstract available


  66. FERRARIS C, Ballestra B, Listorti C, Cappelletti V, et al
    Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen.
    Breast Cancer Res Treat. 2020 Jan 24. pii: 10.1007/s10549-020-05534.
    PubMed     Text format     Abstract available


  67. LEE C, Check DK, Manace Brenman L, Kushi LH, et al
    Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Breast Cancer Res Treat. 2020 Jan 23. pii: 10.1007/s10549-020-05539.
    PubMed     Text format     Abstract available


  68. LI J, Fu F, Yu L, Huang M, et al
    Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05528.
    PubMed     Text format     Abstract available


  69. BANSOD S, Desai R
    Nationwide prevalence and trends of acute cardiovascular and cerebrovascular events among adult breast cancer survivors with a history of radiation therapy.
    Breast Cancer Res Treat. 2020 Jan 22. pii: 10.1007/s10549-020-05535.
    PubMed     Text format    


  70. FAYANJU OM, Ren Y, Greenup RA, Plichta JK, et al
    Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients.
    Breast Cancer Res Treat. 2020 Jan 20. pii: 10.1007/s10549-020-05529.
    PubMed     Text format     Abstract available


  71. HULSBERGEN AFC, Cho LD, Mammi M, Lamba N, et al
    Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.
    Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05531.
    PubMed     Text format     Abstract available


  72. MASUDA N, Ohtani S, Takano T, Inoue K, et al
    A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Breast Cancer Res Treat. 2020 Jan 17. pii: 10.1007/s10549-020-05524.
    PubMed     Text format     Abstract available


  73. KLAESTAD E, Opdahl S, Engstrom MJ, Ytterhus B, et al
    MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05532.
    PubMed     Text format     Abstract available


  74. YE ZJ, Zhang Z, Zhang XY, Tang Y, et al
    Effectiveness of adjuvant supportive-expressive group therapy for breast cancer.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05526.
    PubMed     Text format     Abstract available


  75. GARCIA X, Elia A, Galizzi L, May M, et al
    Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05527.
    PubMed     Text format     Abstract available


  76. LOPEZ G, Fusco N
    RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2020 Jan 16. pii: 10.1007/s10549-020-05530.
    PubMed     Text format    


  77. ROTILI A, Trimboli RM, Penco S, Pesapane F, et al
    Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05519.
    PubMed     Text format     Abstract available


  78. BJERKESET E, Rohrl K, Schou-Bredal I
    Symptom cluster of pain, fatigue, and psychological distress in breast cancer survivors: prevalence and characteristics.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-020-05522.
    PubMed     Text format     Abstract available


  79. TADROS AB, Moo TA, Stempel M, Zabor EC, et al
    Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
    Breast Cancer Res Treat. 2020 Jan 14. pii: 10.1007/s10549-019-05520.
    PubMed     Text format     Abstract available


  80. YAO S, Laurent CA, Roh JM, Lo J, et al
    Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
    Breast Cancer Res Treat. 2020 Jan 7. pii: 10.1007/s10549-019-05518.
    PubMed     Text format     Abstract available


  81. WIJAYABAHU AT, Egan KM, Yaghjyan L
    Uterine cancer in breast cancer survivors: a systematic review.
    Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05516.
    PubMed     Text format     Abstract available


  82. KIM SS, Lee MH, Lee MO
    Histone methyltransferases regulate the transcriptional expression of ERalpha and the proliferation of tamoxifen-resistant breast cancer cells.
    Breast Cancer Res Treat. 2020 Jan 2. pii: 10.1007/s10549-019-05517.
    PubMed     Text format     Abstract available


  83. TYNAN M, Peshkin BN, Isaacs C, Willey S, et al
    Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2020 Jan 1. pii: 10.1007/s10549-019-05515.
    PubMed     Text format     Abstract available


  84. VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
    Authors' reply to the comment "Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism".
    Breast Cancer Res Treat. 2020;179:519-520.
    PubMed     Text format    


    December 2019
  85. LI Y, Zhou Y, Mao F, Lin Y, et al
    Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
    Breast Cancer Res Treat. 2019 Dec 21. pii: 10.1007/s10549-019-05513.
    PubMed     Text format     Abstract available


  86. CHEN HL, Du L, Li XM
    Re: Association of depression and anxiety disorder with the risk of mortality in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 19. pii: 10.1007/s10549-019-05510.
    PubMed     Text format    


  87. HEUBLEIN S, Egger M, Zhu J, Berger L, et al
    Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 11. pii: 10.1007/s10549-019-05503.
    PubMed     Text format     Abstract available


  88. KIM MH, Kim GM, Kim JH, Kim JY, et al
    Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Breast Cancer Res Treat. 2019 Dec 6. pii: 10.1007/s10549-019-05505.
    PubMed     Text format     Abstract available


  89. YASRI S, Wiwanitkit V
    Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism.
    Breast Cancer Res Treat. 2019;178:713.
    PubMed     Text format    


    November 2019
  90. HII LW, Chung FF, Soo JS, Tan BS, et al
    Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
    Breast Cancer Res Treat. 2019 Nov 29. pii: 10.1007/s10549-019-05504.
    PubMed     Text format     Abstract available


  91. CLAESSENS AKM, Timman R, Busschbach JJ, Bouma JM, et al
    The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer.
    Breast Cancer Res Treat. 2019 Nov 28. pii: 10.1007/s10549-019-05495.
    PubMed     Text format     Abstract available


  92. ANDERSEN JLM, Hansen L, Thomsen BLR, Christiansen LR, et al
    Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort.
    Breast Cancer Res Treat. 2019 Nov 26. pii: 10.1007/s10549-019-05497.
    PubMed     Text format     Abstract available


  93. WU Y, Ouyang T, Li J, Wang T, et al
    Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2019 Nov 25. pii: 10.1007/s10549-019-05483.
    PubMed     Text format     Abstract available


  94. KULIGINA ES, Sokolenko AP, Bizin IV, Romanko AA, et al
    Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39.
    Breast Cancer Res Treat. 2019 Nov 21. pii: 10.1007/s10549-019-05492.
    PubMed     Text format     Abstract available


  95. ALMEIDA M, Soares M, Ramalhinho AC, Moutinho JF, et al
    The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.
    Breast Cancer Res Treat. 2019 Nov 19. pii: 10.1007/s10549-019-05494.
    PubMed     Text format     Abstract available


  96. FERNANDEZ AI, Geng X, Chaldekas K, Harris B, et al
    The orphan nuclear receptor estrogen-related receptor beta (ERRbeta) in triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Nov 19. pii: 10.1007/s10549-019-05485.
    PubMed     Text format     Abstract available


  97. ROSENBERGER LH, Ren Y, Thomas SM, Greenup RA, et al
    Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?
    Breast Cancer Res Treat. 2019 Nov 18. pii: 10.1007/s10549-019-05500.
    PubMed     Text format     Abstract available


  98. FRISELL A, Lagergren J, Halle M, de Boniface J, et al
    Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information.
    Breast Cancer Res Treat. 2019 Nov 18. pii: 10.1007/s10549-019-05496.
    PubMed     Text format     Abstract available


  99. NYROP KA, Deal AM, Shachar SS, Park J, et al
    Weight trajectories in women receiving systemic adjuvant therapy for breast cancer.
    Breast Cancer Res Treat. 2019 Nov 16. pii: 10.1007/s10549-019-05501.
    PubMed     Text format     Abstract available


  100. WARDELL SE, Yllanes AP, Chao CA, Bae Y, et al
    Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy.
    Breast Cancer Res Treat. 2019 Nov 16. pii: 10.1007/s10549-019-05498.
    PubMed     Text format     Abstract available


  101. DREWS-ELGER K, Sandoval-Leon AC, Ergonul AB, Jegg AM, et al
    Paget's disease of the nipple in a Her2-positive breast cancer xenograft model.
    Breast Cancer Res Treat. 2019 Nov 13. pii: 10.1007/s10549-019-05490.
    PubMed     Text format     Abstract available


  102. TIAINEN S, Masarwah A, Oikari S, Rilla K, et al
    Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis.
    Breast Cancer Res Treat. 2019 Nov 12. pii: 10.1007/s10549-019-05491.
    PubMed     Text format     Abstract available


  103. KANSTRUP C, Teilum D, Rejnmark L, Bigaard JV, et al
    25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival.
    Breast Cancer Res Treat. 2019 Nov 9. pii: 10.1007/s10549-019-05486.
    PubMed     Text format     Abstract available


  104. KUROZUMI S, Alsaeed S, Orah N, Miligy IM, et al
    Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.
    Breast Cancer Res Treat. 2019 Nov 9. pii: 10.1007/s10549-019-05488.
    PubMed     Text format     Abstract available


  105. CAO S, Wei F, Zhou J, Zhu Z, et al
    The synergistic effect between adult weight changes and CYP24A1 polymorphisms is associated with pre- and postmenopausal breast cancer risk.
    Breast Cancer Res Treat. 2019 Nov 6. pii: 10.1007/s10549-019-05484.
    PubMed     Text format     Abstract available


  106. KARIRI YA, Joseph C, Kurozumi S, Toss MS, et al
    Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
    Breast Cancer Res Treat. 2019 Nov 2. pii: 10.1007/s10549-019-05466.
    PubMed     Text format     Abstract available


  107. STRIZOVA Z, Vachtenheim J Jr, Bartunkova J
    The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression.
    Breast Cancer Res Treat. 2019;178:247-248.
    PubMed     Text format    


  108. TRIMBOLI RM, Schiaffino S, Sardanelli F
    In BRCA mutation carriers breast conserving surgery may not be the best choice.
    Breast Cancer Res Treat. 2019;178:245-246.
    PubMed     Text format    


    October 2019
  109. SHIM EJ, Lee JW, Cho J, Jung HK, et al
    Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.
    Breast Cancer Res Treat. 2019 Oct 31. pii: 10.1007/s10549-019-05479.
    PubMed     Text format     Abstract available


  110. SRIDHAR S, Rajesh C, Jishnu PV, Jayaram P, et al
    Increased expression of P-cadherin is an indicator of poor prognosis in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Oct 29. pii: 10.1007/s10549-019-05477.
    PubMed     Text format     Abstract available


  111. ZHENG L, Li X, Gu Y, Lv X, et al
    Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
    Breast Cancer Res Treat. 2019 Oct 26. pii: 10.1007/s10549-019-05478.
    PubMed     Text format     Abstract available


  112. BATENBURG MCT, Gregorowitsch ML, Maarse W, Witkamp A, et al
    Patient-reported cosmetic satisfaction and the long-term association with quality of life in irradiated breast cancer patients.
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05470.
    PubMed     Text format     Abstract available


  113. CHOI Y, Smith KC, Shukla A, Blackford AL, et al
    Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines?
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05480.
    PubMed     Text format     Abstract available


  114. BEDNAREK R, Selmi A, Wojkowska D, Karolczak K, et al
    Functional inhibition of F11 receptor (F11R/junctional adhesion molecule-A/JAM-A) activity by a F11R-derived peptide in breast cancer and its microenvironment.
    Breast Cancer Res Treat. 2019 Oct 24. pii: 10.1007/s10549-019-05471.
    PubMed     Text format     Abstract available


  115. BANYS-PALUCHOWSKI M, Milde-Langosch K, Fehm T, Witzel I, et al
    Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients.
    Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05474.
    PubMed     Text format     Abstract available


  116. KOMOROWSKI AS, Pezo RC
    Untapped "-omics": the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment.
    Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05472.
    PubMed     Text format     Abstract available


  117. LEE YJ, Park H, Kang CM, Gwark SC, et al
    Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer.
    Breast Cancer Res Treat. 2019 Oct 23. pii: 10.1007/s10549-019-05469.
    PubMed     Text format     Abstract available


  118. NAIK H, Leung B, Laskin J, McDonald M, et al
    Emotional distress and psychosocial needs in patients with breast cancer in British Columbia: younger versus older adults.
    Breast Cancer Res Treat. 2019 Oct 19. pii: 10.1007/s10549-019-05468.
    PubMed     Text format     Abstract available


  119. JEONG SH, An Y, Ahn C, Park B, et al
    Body mass index and risk of breast cancer molecular subtypes in Korean women: a case-control study.
    Breast Cancer Res Treat. 2019 Oct 18. pii: 10.1007/s10549-019-05451.
    PubMed     Text format     Abstract available


  120. IWASE T, Sangai T, Fujimoto H, Sawabe Y, et al
    Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer.
    Breast Cancer Res Treat. 2019 Oct 16. pii: 10.1007/s10549-019-05467.
    PubMed     Text format     Abstract available


  121. CARENE D, Tran-Dien A, Lemonnier J, Dalenc F, et al
    Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
    Breast Cancer Res Treat. 2019 Oct 16. pii: 10.1007/s10549-019-05462.
    PubMed     Text format     Abstract available


  122. HERRSCHER H, Velten M, Leblanc J, Kalish-Weindling M, et al
    Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Oct 14. pii: 10.1007/s10549-019-05439.
    PubMed     Text format     Abstract available


  123. RODRIGUES-FERREIRA S, Molina A, Nahmias C
    Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer.
    Breast Cancer Res Treat. 2019 Oct 12. pii: 10.1007/s10549-019-05463.
    PubMed     Text format     Abstract available


  124. QIAN X, Li Z, Ruan G, Tu C, et al
    Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2019 Oct 12. pii: 10.1007/s10549-019-05464.
    PubMed     Text format     Abstract available


  125. AMMITZBOLL G, Andersen KG, Bidstrup PE, Johansen C, et al
    Effect of progressive resistance training on persistent pain after axillary dissection in breast cancer: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 Oct 11. pii: 10.1007/s10549-019-05461.
    PubMed     Text format     Abstract available


  126. SHI Z, Rundle A, Genkinger JM, Cheung YK, et al
    Distinct trajectories of fruits and vegetables, dietary fat, and alcohol intake following a breast cancer diagnosis: the Pathways Study.
    Breast Cancer Res Treat. 2019 Oct 10. pii: 10.1007/s10549-019-05457.
    PubMed     Text format     Abstract available


  127. ALJOHANI AI, Toss MS, Kurozumi S, Joseph C, et al
    The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
    Breast Cancer Res Treat. 2019 Oct 10. pii: 10.1007/s10549-019-05459.
    PubMed     Text format     Abstract available


  128. GONZALEZ-RODRIGUEZ E, Aubry-Rozier B, Stoll D, Zaman K, et al
    Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
    Breast Cancer Res Treat. 2019 Oct 9. pii: 10.1007/s10549-019-05458.
    PubMed     Text format     Abstract available


  129. HWANG KT, Kim J, Jung J, Kim BH, et al
    Long-term prognostic effect of hormone receptor subtype on breast cancer.
    Breast Cancer Res Treat. 2019 Oct 8. pii: 10.1007/s10549-019-05456.
    PubMed     Text format     Abstract available


  130. BLANCHETTE PS, Lam M, Richard L, Allen B, et al
    Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Breast Cancer Res Treat. 2019 Oct 1. pii: 10.1007/s10549-019-05430.
    PubMed     Text format     Abstract available


    September 2019
  131. WARDELL SE, Yllanes AP, Chao CA, Bae Y, et al
    Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-alpha degrader activity in antitumor efficacy.
    Breast Cancer Res Treat. 2019 Sep 27. pii: 10.1007/s10549-019-05454.
    PubMed     Text format     Abstract available


  132. SAMUEL CA, Spencer JC, Rosenstein DL, Reeder-Hayes KE, et al
    Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Sep 25. pii: 10.1007/s10549-019-05449.
    PubMed     Text format     Abstract available


  133. PU M, Messer K, Davies SR, Vickery TL, et al
    Research-based PAM50 signature and long-term breast cancer survival.
    Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05446.
    PubMed     Text format     Abstract available


  134. YEN TWF, Laud PW, McGinley EL, Pezzin LE, et al
    Prevalence and scope of advanced practice provider oncology care among Medicare beneficiaries with breast cancer.
    Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05447.
    PubMed     Text format     Abstract available


  135. WOLFS JAGN, de Joode LGEH, van der Hulst RRWJ, Qiu SS, et al
    Correlation between patency and clinical improvement after lymphaticovenous anastomosis (LVA) in breast cancer-related lymphedema: 12-month follow-up.
    Breast Cancer Res Treat. 2019 Sep 21. pii: 10.1007/s10549-019-05450.
    PubMed     Text format     Abstract available


  136. JEON J, Kim SE, Lee DY, Choi D, et al
    Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies.
    Breast Cancer Res Treat. 2019 Sep 20. pii: 10.1007/s10549-019-05448.
    PubMed     Text format     Abstract available


  137. LEONE JP, Duda DG, Hu J, Barry WT, et al
    A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2019 Sep 20. pii: 10.1007/s10549-019-05445.
    PubMed     Text format     Abstract available


  138. SYNNOTT NC, O'Connell D, Crown J, Duffy MJ, et al
    COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2019 Sep 19. pii: 10.1007/s10549-019-05435.
    PubMed     Text format     Abstract available


  139. TERADA M, Yoshimura A, Sawaki M, Hattori M, et al
    Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05443.
    PubMed     Text format     Abstract available


  140. ALLOTT EH, Shan Y, Chen M, Sun X, et al
    Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05442.
    PubMed     Text format     Abstract available


  141. VANGANGELT KMH, Kramer CJH, Bastiaannet E, Putter H, et al
    The intra-tumoural stroma in patients with breast cancer increases with age.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05422.
    PubMed     Text format     Abstract available


  142. BATTISTI NML, True V, Chaabouni N, Chopra N, et al
    Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience.
    Breast Cancer Res Treat. 2019 Sep 18. pii: 10.1007/s10549-019-05444.
    PubMed     Text format     Abstract available


  143. GORBOUNOV M, Carleton NM, Asch-Kendrick RJ, Xian L, et al
    High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer.
    Breast Cancer Res Treat. 2019 Sep 17. pii: 10.1007/s10549-019-05419.
    PubMed     Text format     Abstract available


  144. PINARD C, Debled M, Ben Rejeb H, Velasco V, et al
    Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 Sep 16. pii: 10.1007/s10549-019-05437.
    PubMed     Text format     Abstract available


  145. CHENG AS, Leung SCY, Gao D, Burugu S, et al
    Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
    Breast Cancer Res Treat. 2019 Sep 14. pii: 10.1007/s10549-019-05438.
    PubMed     Text format     Abstract available


  146. BRINKHAUS B, Kirschbaum B, Stockigt B, Binting S, et al
    Prophylactic acupuncture treatment during chemotherapy with breast cancer: a randomized pragmatic trial with a retrospective nested qualitative study.
    Breast Cancer Res Treat. 2019 Sep 13. pii: 10.1007/s10549-019-05431.
    PubMed     Text format     Abstract available


  147. DU T, Liu B, Wang Z, Wan X, et al
    CpG methylation signature predicts prognosis in breast cancer.
    Breast Cancer Res Treat. 2019 Sep 13. pii: 10.1007/s10549-019-05417.
    PubMed     Text format     Abstract available


  148. DE LIGT KM, Heins M, Verloop J, Ezendam NPM, et al
    The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors.
    Breast Cancer Res Treat. 2019 Sep 11. pii: 10.1007/s10549-019-05433.
    PubMed     Text format     Abstract available


  149. SCARPITTA R, Zanna I, Aretini P, Gambino G, et al
    Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing.
    Breast Cancer Res Treat. 2019 Sep 11. pii: 10.1007/s10549-019-05429.
    PubMed     Text format     Abstract available


  150. COUGHLIN SS, Caplan LS, Williams V
    Home-based physical activity interventions for breast cancer patients receiving primary therapy: a systematic review.
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05424.
    PubMed     Text format     Abstract available


  151. STEENBRUGGEN TG, Bouwer NI, Smorenburg CH, Rier HN, et al
    Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05427.
    PubMed     Text format     Abstract available


  152. JEON YW, You SH, Lee JE, Youn HJ, et al
    Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis.
    Breast Cancer Res Treat. 2019 Sep 6. pii: 10.1007/s10549-019-05426.
    PubMed     Text format     Abstract available


  153. KACZMAREK E, Saint-Martin C, Pierga JY, Brain E, et al
    Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
    Breast Cancer Res Treat. 2019 Sep 5. pii: 10.1007/s10549-019-05423.
    PubMed     Text format     Abstract available


  154. LAGACE F, Ghazawi FM, Le M, Rahme E, et al
    Analysis of incidence, mortality trends, and geographic distribution of breast cancer patients in Canada.
    Breast Cancer Res Treat. 2019 Sep 4. pii: 10.1007/s10549-019-05418.
    PubMed     Text format     Abstract available


  155. RIEDEL F, Heil J, Feisst M, Rezai M, et al
    Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Breast Cancer Res Treat. 2019;177:457-467.
    PubMed     Text format     Abstract available


  156. NIRAVATH P, Hilsenbeck SG, Wang T, Jiralerspong S, et al
    Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
    Breast Cancer Res Treat. 2019;177:427-435.
    PubMed     Text format     Abstract available


  157. BLACKWOOD J, Wright FC, Hong NJL, Gagliardi AR, et al
    Quality of DCIS information on the internet: a content analysis.
    Breast Cancer Res Treat. 2019;177:295-305.
    PubMed     Text format     Abstract available


  158. YU Q, Huang K, Zhu Y, Chen X, et al
    Preliminary results of computer-aided diagnosis for magnetic resonance imaging of solid breast lesions.
    Breast Cancer Res Treat. 2019;177:419-426.
    PubMed     Text format     Abstract available


  159. YANG Y, Li S, Liu G, Shao Z, et al
    Is core needle biopsy effective at diagnosing male breast lesions?
    Breast Cancer Res Treat. 2019;177:507-511.
    PubMed     Text format     Abstract available


    August 2019
  160. LI C, Fan H, Xiang Q, Xu L, et al
    Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05421.
    PubMed     Text format     Abstract available


  161. HOVELING LA, van Maaren MC, Hueting T, Strobbe LJA, et al
    Validation of the online prediction model CancerMath in the Dutch breast cancer population.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05399.
    PubMed     Text format     Abstract available


  162. ALFARSI LH, Ansari RE, Craze ML, Toss MS, et al
    CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
    Breast Cancer Res Treat. 2019 Aug 30. pii: 10.1007/s10549-019-05420.
    PubMed     Text format     Abstract available


  163. KLUZNIAK W, Wokolorczyk D, Rusak B, Huzarski T, et al
    Inherited variants in XRCC2 and the risk of breast cancer.
    Breast Cancer Res Treat. 2019 Aug 28. pii: 10.1007/s10549-019-05415.
    PubMed     Text format     Abstract available


  164. ZHI WI, Chen P, Kwon A, Chen C, et al
    Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
    Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05416.
    PubMed     Text format     Abstract available


  165. CHEN J, Douglass J, Prasath V, Neace M, et al
    The microbiome and breast cancer: a review.
    Breast Cancer Res Treat. 2019 Aug 27. pii: 10.1007/s10549-019-05407.
    PubMed     Text format     Abstract available


  166. KUBO M, Kawai M, Kumamaru H, Miyata H, et al
    A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05413.
    PubMed     Text format     Abstract available


  167. VERBEEK JGE, Atema V, Mewes JC, van Leeuwen M, et al
    Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05410.
    PubMed     Text format     Abstract available


  168. DE BOER AZ, Bastiaannet E, de Glas NA, Marang-van de Mheen PJ, et al
    Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05412.
    PubMed     Text format     Abstract available


  169. D'AMBROSIO V, Vena F, Di Mascio D, Faralli I, et al
    Obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Aug 26. pii: 10.1007/s10549-019-05408.
    PubMed     Text format     Abstract available


  170. CERRETINI R, Mercado G, Morganstein J, Schiaffi J, et al
    Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Breast Cancer Res Treat. 2019 Aug 24. pii: 10.1007/s10549-019-05411.
    PubMed     Text format     Abstract available


  171. LUNDGREN C, Bendahl PO, Borg A, Ehinger A, et al
    Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05378.
    PubMed     Text format     Abstract available


  172. SIDDAPPA CM, Pillai SG, Snider J, Alldredge P, et al
    Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05405.
    PubMed     Text format     Abstract available


  173. BATTISTI NML, Tong D, Ring A, Smith I, et al
    Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience.
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05406.
    PubMed     Text format     Abstract available


  174. WANG X, Kong X, Fang Y, Wang J, et al
    Letter regarding Sopik V et al. entitled "Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ".
    Breast Cancer Res Treat. 2019 Aug 20. pii: 10.1007/s10549-019-05389.
    PubMed     Text format    


  175. ROCCA A, Melegari E, Palleschi M
    Precision medicine: PI3K targeting in advanced breast cancer.
    Breast Cancer Res Treat. 2019 Aug 19. pii: 10.1007/s10549-019-05409.
    PubMed     Text format    


  176. VIALE G, Hanlon Newell AE, Walker E, Harlow G, et al
    Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes.
    Breast Cancer Res Treat. 2019 Aug 17. pii: 10.1007/s10549-019-05402.
    PubMed     Text format     Abstract available


  177. EAGLEHOUSE YL, Georg MW, Shriver CD, Zhu K, et al
    Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system.
    Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05404.
    PubMed     Text format     Abstract available


  178. BARRETO-COELHO P, Cerbon D, Schlumbrecht M, Parra CM, et al
    Differences in breast cancer outcomes amongst Black US-born and Caribbean-born immigrants.
    Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05403.
    PubMed     Text format     Abstract available


  179. LIU YL, Wang DW, Yang ZC, Ma R, et al
    Marital status is an independent prognostic factor in inflammatory breast cancer patients: an analysis of the surveillance, epidemiology, and end results database.
    Breast Cancer Res Treat. 2019 Aug 14. pii: 10.1007/s10549-019-05385.
    PubMed     Text format     Abstract available


  180. LAI CPT, Yeong JPS, Tan AS, Ong CHC, et al
    Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence.
    Breast Cancer Res Treat. 2019 Aug 13. pii: 10.1007/s10549-019-05396.
    PubMed     Text format     Abstract available


  181. RUSAK B, Kluzniak W, Wokolorczyk D, Stempa K, et al
    Allelic modification of breast cancer risk in women with an NBN mutation.
    Breast Cancer Res Treat. 2019 Aug 13. pii: 10.1007/s10549-019-05391.
    PubMed     Text format     Abstract available


  182. KIM JY, Lee E, Park K, Im SA, et al
    Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
    Breast Cancer Res Treat. 2019 Aug 12. pii: 10.1007/s10549-019-05400.
    PubMed     Text format     Abstract available


  183. HIDA AI, Watanabe T, Sagara Y, Kashiwaba M, et al
    Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Aug 12. pii: 10.1007/s10549-019-05390.
    PubMed     Text format     Abstract available


  184. TANG E, Rowland A, McKinnon RA, Sorich MJ, et al
    Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.
    Breast Cancer Res Treat. 2019 Aug 9. pii: 10.1007/s10549-019-05393.
    PubMed     Text format     Abstract available


  185. ARNAOUT A, Robertson S, Pond GR, Vieth R, et al
    Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients.
    Breast Cancer Res Treat. 2019 Aug 9. pii: 10.1007/s10549-019-05392.
    PubMed     Text format     Abstract available


  186. ROBINSON A, Stober C, Fergusson D, Kehoe A, et al
    A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy.
    Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05388.
    PubMed     Text format     Abstract available


  187. ARNAOUT A, Robertson SJ, Pond GR, Lee H, et al
    A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients.
    Breast Cancer Res Treat. 2019 Aug 7. pii: 10.1007/s10549-019-05381.
    PubMed     Text format     Abstract available


  188. LIU ZB, Ezzedine NE, Eterovic AK, Ensor JE, et al
    Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05374.
    PubMed     Text format     Abstract available


  189. HE J, McLaughlin RP, van der Noord V, Foekens JA, et al
    Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05380.
    PubMed     Text format     Abstract available


  190. LIU Y, Wu S, Shi X, Luo Y, et al
    HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
    Breast Cancer Res Treat. 2019 Aug 6. pii: 10.1007/s10549-019-05387.
    PubMed     Text format     Abstract available


  191. PEARSON A, Booker A, Tio M, Marx G, et al
    Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study.
    Breast Cancer Res Treat. 2019 Aug 3. pii: 10.1007/s10549-019-05384.
    PubMed     Text format     Abstract available


  192. ALTUNDAG K
    HER2+ and triple-negative phenotypes in invasive lobular carcinoma might have different specific biological features.
    Breast Cancer Res Treat. 2019;176:719.
    PubMed     Text format    


  193. ZDRAVKOVIC D, Ivanovic N, Crnokrak B
    Microinvasion: could it be sufficient diagnostic criteria for the optimal treatment decision?
    Breast Cancer Res Treat. 2019;176:717.
    PubMed     Text format    


  194. ZHANG L, Bailleul J, Yazal T, Dong K, et al
    PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.
    Breast Cancer Res Treat. 2019 Aug 1. pii: 10.1007/s10549-019-05376.
    PubMed     Text format     Abstract available


  195. ANGARITA FA, Dossa F, Zuckerman J, McCready DR, et al
    Is immediate breast reconstruction safe in women over 70? An analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2019;177:215-224.
    PubMed     Text format     Abstract available


  196. HELLAND T, Hagen KB, Haugstoyl ME, Kvaloy JT, et al
    Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database.
    Breast Cancer Res Treat. 2019;177:185-195.
    PubMed     Text format     Abstract available


  197. MARMOR S, Altman AM, Mayleben WT, Hui JYC, et al
    The use of contralateral prophylactic mastectomy among elderly patients in the United States.
    Breast Cancer Res Treat. 2019;177:175-183.
    PubMed     Text format     Abstract available


  198. CHEN XY, Yeong J, Thike AA, Bay BH, et al
    Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
    Breast Cancer Res Treat. 2019;177:17-27.
    PubMed     Text format     Abstract available


  199. ALTUNDAG K
    ER(+)/HER2(+) and ER-/HER2(+) breast cancers might have different intracranial recurrence patterns after brain-directed radiation for brain metastases.
    Breast Cancer Res Treat. 2019;177:233.
    PubMed     Text format    


  200. MALTONI R, Bravaccini S
    What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?
    Breast Cancer Res Treat. 2019;177:231-232.
    PubMed     Text format    


    July 2019
  201. ABRAMSON VG, Oliveira M, Cervantes A, Wildiers H, et al
    A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jul 31. pii: 10.1007/s10549-019-05360.
    PubMed     Text format     Abstract available


  202. VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
    Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism in Brazilian breast cancer patients: association with susceptibility, clinicopathological features, and interaction with TGFB1 haplotypes.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05370.
    PubMed     Text format     Abstract available


  203. ZHOU H, Wang XJ, Jiang X, Qian Z, et al
    Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05375.
    PubMed     Text format     Abstract available


  204. GOTTSCHAU M, Jensen A, Reinholdt K, Guleria S, et al
    Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study.
    Breast Cancer Res Treat. 2019 Jul 30. pii: 10.1007/s10549-019-05369.
    PubMed     Text format     Abstract available


  205. HUANG W, Ran R, Shao B, Li H, et al
    Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2019 Jul 29. pii: 10.1007/s10549-019-05371.
    PubMed     Text format     Abstract available


  206. DEL RE M, Bertolini I, Crucitta S, Fontanelli L, et al
    Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Jul 26. pii: 10.1007/s10549-019-05365.
    PubMed     Text format     Abstract available


  207. KIM EK, Park AK, Ko E, Park WY, et al
    Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05366.
    PubMed     Text format     Abstract available


  208. VROMANS R, Tenfelde K, Pauws S, van Eenbergen M, et al
    Assessing the quality and communicative aspects of patient decision aids for early-stage breast cancer treatment: a systematic review.
    Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05351.
    PubMed     Text format     Abstract available


  209. ZHOU K, Li J, Li X
    Effects of cyclic adjustment training delivered via a mobile device on psychological resilience, depression, and anxiety in Chinese post-surgical breast cancer patients.
    Breast Cancer Res Treat. 2019 Jul 24. pii: 10.1007/s10549-019-05368.
    PubMed     Text format     Abstract available


  210. SAYYAD MR, Puchalapalli M, Vergara NG, Wangensteen SM, et al
    Syndecan-1 facilitates breast cancer metastasis to the brain.
    Breast Cancer Res Treat. 2019 Jul 20. pii: 10.1007/s10549-019-05347.
    PubMed     Text format     Abstract available


  211. DE GLAS N, Bastiaannet E, de Boer A, Siesling S, et al
    Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study.
    Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05356.
    PubMed     Text format     Abstract available


  212. ADEMUYIWA FO, Salyer P, Ma Y, Fisher S, et al
    Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
    Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05359.
    PubMed     Text format     Abstract available


  213. SAKAI T, Ozkurt E, DeSantis S, Wong SM, et al
    National trends of synchronous bilateral breast cancer incidence in the United States.
    Breast Cancer Res Treat. 2019 Jul 19. pii: 10.1007/s10549-019-05363.
    PubMed     Text format     Abstract available


  214. HUERTA JM, Molina AJ, Chirlaque MD, Yepes P, et al
    Domain-specific patterns of physical activity and risk of breast cancer sub-types in the MCC-Spain study.
    Breast Cancer Res Treat. 2019 Jul 17. pii: 10.1007/s10549-019-05358.
    PubMed     Text format     Abstract available


  215. NAM SE, Lim W, Jeong J, Lee S, et al
    The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
    Breast Cancer Res Treat. 2019 Jul 16. pii: 10.1007/s10549-019-05357.
    PubMed     Text format     Abstract available


  216. ISNALDI E, Ferraioli D, Ferrando L, Brohee S, et al
    Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 12. pii: 10.1007/s10549-019-05348.
    PubMed     Text format     Abstract available


  217. JOHNSON HM, Irish W, Muzaffar M, Vohra NA, et al
    Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05353.
    PubMed     Text format     Abstract available


  218. JACOT W, Dalenc F, Lopez-Crapez E, Chaltiel L, et al
    PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05349.
    PubMed     Text format     Abstract available


  219. ALEIXO GFP, Williams GR, Nyrop KA, Muss HB, et al
    Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.
    Breast Cancer Res Treat. 2019 Jul 11. pii: 10.1007/s10549-019-05352.
    PubMed     Text format     Abstract available


  220. KUROZUMI S, Kaira K, Matsumoto H, Hirakata T, et al
    beta2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jul 9. pii: 10.1007/s10549-019-05341.
    PubMed     Text format     Abstract available


  221. MURATA T, Yanagisawa T, Kurihara T, Kaneko M, et al
    Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination.
    Breast Cancer Res Treat. 2019 Jul 8. pii: 10.1007/s10549-019-05330.
    PubMed     Text format     Abstract available


  222. MARINO MA, Gucalp A, Leithner D, Keating D, et al
    Mammographic screening in male patients at high risk for breast cancer: is it worth it?
    Breast Cancer Res Treat. 2019 Jul 6. pii: 10.1007/s10549-019-05338.
    PubMed     Text format     Abstract available


  223. YEO W, Ueno T, Lin CH, Liu Q, et al
    Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
    Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05318.
    PubMed     Text format     Abstract available


  224. HARBORG S, Cronin-Fenton DP, Borgquist S
    RE.: Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 4. pii: 10.1007/s10549-019-05337.
    PubMed     Text format    


  225. COUGHLIN SS
    Social determinants of breast cancer risk, stage, and survival.
    Breast Cancer Res Treat. 2019 Jul 3. pii: 10.1007/s10549-019-05340.
    PubMed     Text format     Abstract available


  226. ZEINDLER J, Angehrn F, Droeser R, Daster S, et al
    Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer.
    Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05336.
    PubMed     Text format     Abstract available


  227. SASADA S, Shiroma N, Goda N, Kajitani K, et al
    The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer.
    Breast Cancer Res Treat. 2019 Jul 2. pii: 10.1007/s10549-019-05339.
    PubMed     Text format     Abstract available


  228. BAS O, Dizdar O
    Classifying sarcopenia: using median value or cut-off values?
    Breast Cancer Res Treat. 2019;176:479.
    PubMed     Text format    


  229. GIANNAKEAS V, Narod SA
    A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy.
    Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05334.
    PubMed     Text format     Abstract available


  230. PUVANESARAJAH S, Gapstur SM, Patel AV, Sherman ME, et al
    Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II.
    Breast Cancer Res Treat. 2019 Jul 1. pii: 10.1007/s10549-019-05322.
    PubMed     Text format     Abstract available


  231. BEUGELS J, Meijvogel JLW, Tuinder SMH, Tjan-Heijnen VCG, et al
    The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions.
    Breast Cancer Res Treat. 2019;176:367-375.
    PubMed     Text format     Abstract available


  232. WEISS A, Lin H, Babiera GV, Bedrosian I, et al
    Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.
    Breast Cancer Res Treat. 2019;176:435-444.
    PubMed     Text format     Abstract available


  233. DUAZO-CASSIN L, Le Guellec S, Lusque A, Chantalat E, et al
    Breast desmoid tumor management in France: toward a new strategy.
    Breast Cancer Res Treat. 2019;176:329-335.
    PubMed     Text format     Abstract available


  234. BOUNDOUKI G, Wong Sik Hee JR, Croghan N, Stocking K, et al
    Comparing long-term local recurrence rates of surgical and non-surgical management of close anterior margins in breast conserving surgery.
    Breast Cancer Res Treat. 2019;176:311-319.
    PubMed     Text format     Abstract available


  235. RODRIGUES-DUARTE H, van Nijnatten TJA, Khoury T, Cody H, et al
    Does every woman presenting with malignant calcifications require a post lumpectomy mammogram?
    Breast Cancer Res Treat. 2019;176:401-406.
    PubMed     Text format     Abstract available


  236. SPERANSKY S, Serafini P, Caroli J, Bicciato S, et al
    A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
    Breast Cancer Res Treat. 2019;176:271-289.
    PubMed     Text format     Abstract available


  237. MENG P, Vaapil M, Tagmount A, Loguinov A, et al
    Propagation of functional estrogen receptor positive normal human breast cells in 3D cultures.
    Breast Cancer Res Treat. 2019;176:131-140.
    PubMed     Text format     Abstract available


  238. LEE J, Kim HE, Song YS, Cho EY, et al
    miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
    Breast Cancer Res Treat. 2019;176:119-130.
    PubMed     Text format     Abstract available


  239. BAEZ-VALLECILLO L, Raghavendra AS, Hess KR, Barcenas CH, et al
    Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
    Breast Cancer Res Treat. 2019;176:227-234.
    PubMed     Text format     Abstract available


  240. NEALON K, Rebello M, Sobti N, Sherburne A, et al
    Improving surgical efficiency of immediate implant-based breast reconstruction following mastectomy.
    Breast Cancer Res Treat. 2019;176:159-164.
    PubMed     Text format     Abstract available


  241. MONTAGNE L, Gal J, Chand ME, Schiappa R, et al
    GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event.
    Breast Cancer Res Treat. 2019;176:149-157.
    PubMed     Text format     Abstract available


    June 2019
  242. LI E, Guida JL, Tian Y, Sung H, et al
    Associations between mammographic density and tumor characteristics in Chinese women with breast cancer.
    Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05325.
    PubMed     Text format     Abstract available


  243. KOROBEYNIKOV V, Borakove M, Feng Y, Wuest WM, et al
    Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
    Breast Cancer Res Treat. 2019 Jun 28. pii: 10.1007/s10549-019-05329.
    PubMed     Text format     Abstract available


  244. MICHEL LL, Sommer L, Gonzalez Silos R, Lorenzo Bermejo J, et al
    Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05314.
    PubMed     Text format     Abstract available


  245. NEWELL M, Goruk S, Mazurak V, Postovit L, et al
    Role of docosahexaenoic acid in enhancement of docetaxel action in patient-derived breast cancer xenografts.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05331.
    PubMed     Text format     Abstract available


  246. ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
    Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05328.
    PubMed     Text format     Abstract available


  247. LEE K, Kang I, Mack WJ, Mortimer J, et al
    Effects of high-intensity interval training on vascular endothelial function and vascular wall thickness in breast cancer patients receiving anthracycline-based chemotherapy: a randomized pilot study.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05332.
    PubMed     Text format     Abstract available


  248. FORNVIK D, Aaltonen KE, Chen Y, George AM, et al
    Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.
    Breast Cancer Res Treat. 2019 Jun 24. pii: 10.1007/s10549-019-05326.
    PubMed     Text format     Abstract available


  249. GRANT CV, Carver CM, Hastings SD, Ramachandran K, et al
    Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.
    Breast Cancer Res Treat. 2019 Jun 22. pii: 10.1007/s10549-019-05324.
    PubMed     Text format     Abstract available


  250. ISNALDI E, Ferraioli D, Ferrando L, Brohee S, et al
    Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Breast Cancer Res Treat. 2019 Jun 20. pii: 10.1007/s10549-019-05313.
    PubMed     Text format     Abstract available


  251. TURTURRO SB, Najor MS, Yung T, Portt L, et al
    Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
    Breast Cancer Res Treat. 2019 Jun 17. pii: 10.1007/s10549-019-05320.
    PubMed     Text format     Abstract available


  252. SHAWKY MS, Huo CW, Henderson MA, Redfern A, et al
    A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.
    Breast Cancer Res Treat. 2019 Jun 8. pii: 10.1007/s10549-019-05300.
    PubMed     Text format     Abstract available


  253. OLIAI C, Douek ML, Rhoane C, Bhutada A, et al
    Clinical features of pseudocirrhosis in metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jun 7. pii: 10.1007/s10549-019-05311.
    PubMed     Text format     Abstract available


  254. NAYAK D, Katoch A, Sharma D, Faheem MM, et al
    Indolylkojyl methane analogue IKM5 potentially inhibits invasion of breast cancer cells via attenuation of GRP78.
    Breast Cancer Res Treat. 2019 Jun 7. pii: 10.1007/s10549-019-05301.
    PubMed     Text format     Abstract available


  255. DIERAS V, Bonnefoi H, Alba E, Awada A, et al
    Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05305.
    PubMed     Text format     Abstract available


  256. BHANDARI S, Ngo P, Kute B, Mandadi M, et al
    Adherence to anti-estrogen therapy in women with hormone receptor-positive breast cancer utilizing bubble packaging: a pilot study.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05308.
    PubMed     Text format     Abstract available


  257. MELISKO ME, Assefa M, Hwang J, DeLuca A, et al
    Phase II study of irinotecan and temozolomide in breast cancer patients with progressing central nervous system disease.
    Breast Cancer Res Treat. 2019 Jun 6. pii: 10.1007/s10549-019-05309.
    PubMed     Text format     Abstract available


  258. LAO C, Lawrenson R, Edwards M, Campbell I, et al
    Treatment and survival of Asian women diagnosed with breast cancer in New Zealand.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05310.
    PubMed     Text format     Abstract available


  259. JERUSALEM G, Lancellotti P, Kim SB
    HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05303.
    PubMed     Text format     Abstract available


  260. TEYSIR J, Gegechkori N, Wisnivesky JP, Lin JJ, et al
    Correction to: Racial disparities in surveillance mammography among older breast cancer survivors.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05291.
    PubMed     Text format     Abstract available


  261. MURPHY JD, Sandler D, White AJ, O'Brien KM, et al
    Severe acne and risk of breast cancer.
    Breast Cancer Res Treat. 2019 Jun 5. pii: 10.1007/s10549-019-05302.
    PubMed     Text format     Abstract available


  262. WOLFF JL, Aufill J, Echavarria D, Heughan JA, et al
    Sharing in care: engaging care partners in the care and communication of breast cancer patients.
    Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05306.
    PubMed     Text format     Abstract available


  263. PLASTERER C, Tsaih SW, Peck AR, Chervoneva I, et al
    Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.
    Breast Cancer Res Treat. 2019 Jun 4. pii: 10.1007/s10549-019-05307.
    PubMed     Text format     Abstract available


  264. MCCLELLAND S 3RD, Rhome RM, Zellars RC
    Radiation oncology crossword: breast cancer.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05304.
    PubMed     Text format    


  265. ZHAO H, Shen J, Moore SC, Ye Y, et al
    Correction to: Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05292.
    PubMed     Text format     Abstract available


  266. ELFGEN C, Varga Z, Reeve K, Moskovszky L, et al
    The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.
    Breast Cancer Res Treat. 2019 Jun 1. pii: 10.1007/s10549-019-05298.
    PubMed     Text format     Abstract available


  267. POODT IGM, Schipper RJ, de Greef BTA, Vugts G, et al
    Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval.
    Breast Cancer Res Treat. 2019;175:419-428.
    PubMed     Text format     Abstract available


  268. SHECKTER CC, Matros E, Lee GK, Selber JC, et al
    Applying a value-based care framework to post-mastectomy reconstruction.
    Breast Cancer Res Treat. 2019;175:547-551.
    PubMed     Text format     Abstract available


  269. WILLOUGHBY LI, D'Abbondanza JA, Baltzer HL, Mahoney JL, et al
    Body mass index impacts infection rates in immediate autogenous breast reconstruction.
    Breast Cancer Res Treat. 2019;175:765-773.
    PubMed     Text format     Abstract available


  270. BOLAM KA, Mijwel S, Rundqvist H, Wengstrom Y, et al
    Two-year follow-up of the OptiTrain randomised controlled exercise trial.
    Breast Cancer Res Treat. 2019;175:637-648.
    PubMed     Text format     Abstract available


  271. FONT R, Espinas JA, Barnadas A, Izquierdo A, et al
    Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
    Breast Cancer Res Treat. 2019;175:733-740.
    PubMed     Text format     Abstract available


  272. FIGURA NB, Rizk VT, Mohammadi H, Evernden B, et al
    Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy.
    Breast Cancer Res Treat. 2019;175:781-788.
    PubMed     Text format     Abstract available


  273. CLIFTON K, Min Y, Kimmel J, Litton J, et al
    Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population.
    Breast Cancer Res Treat. 2019;175:667-674.
    PubMed     Text format     Abstract available


  274. DEKLERCK E, Denys H, Kreps EO
    Corneal features in trastuzumab emtansine treatment: not a rare occurrence.
    Breast Cancer Res Treat. 2019;175:525-530.
    PubMed     Text format     Abstract available


  275. MCCLELLAND S 3RD, Hatfield J, Degnin C, Chen Y, et al
    Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma.
    Breast Cancer Res Treat. 2019;175:409-418.
    PubMed     Text format     Abstract available


  276. IGNATOV T, Gorbunow F, Eggemann H, Ortmann O, et al
    Loss of HER2 after HER2-targeted treatment.
    Breast Cancer Res Treat. 2019;175:401-408.
    PubMed     Text format     Abstract available


    May 2019
  277. RUIZ-BORREGO M, Guerrero-Zotano A, Bermejo B, Ramos M, et al
    Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
    Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05296.
    PubMed     Text format     Abstract available


  278. JOZSA F, Ahmed M, Baker R, Douek M, et al
    Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer?
    Breast Cancer Res Treat. 2019 May 31. pii: 10.1007/s10549-019-05299.
    PubMed     Text format     Abstract available


  279. SAW S, Lim J, Lim SH, Wong M, et al
    Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice.
    Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05290.
    PubMed     Text format     Abstract available


  280. ROSENBERG SM, Vaz-Luis I, Gong J, Rajagopal PS, et al
    Employment trends in young women following a breast cancer diagnosis.
    Breast Cancer Res Treat. 2019 May 30. pii: 10.1007/s10549-019-05293.
    PubMed     Text format     Abstract available


  281. KRYSTEL-WHITTEMORE M, Xu J, Brogi E, Ventura K, et al
    Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Breast Cancer Res Treat. 2019 May 29. pii: 10.1007/s10549-019-05295.
    PubMed     Text format     Abstract available


  282. LAMBERTINI M, Campbell C, Gelber RD, Viale G, et al
    Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
    Breast Cancer Res Treat. 2019 May 27. pii: 10.1007/s10549-019-05284.
    PubMed     Text format     Abstract available


  283. ENGMANN NJ, Scott CG, Jensen MR, Winham S, et al
    Combined effect of volumetric breast density and body mass index on breast cancer risk.
    Breast Cancer Res Treat. 2019 May 25. pii: 10.1007/s10549-019-05283.
    PubMed     Text format     Abstract available


  284. JOHNSON HM, Irish W, Vohra NA, Wong JH, et al
    The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05285.
    PubMed     Text format     Abstract available


  285. BASULAIMAN B, Awan AA, Fergusson D, Vandermeer L, et al
    Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT).
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05274.
    PubMed     Text format     Abstract available


  286. PINEDA-MONCUSI M, Servitja S, Tusquets I, Diez-Perez A, et al
    Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05289.
    PubMed     Text format     Abstract available


  287. DONG B, Xie C, Jing X, Lin L, et al
    Yoga has a solid effect on cancer-related fatigue in patients with breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2019 May 24. pii: 10.1007/s10549-019-05278.
    PubMed     Text format     Abstract available


  288. PRAWIRA A, Munusamy P, Yuan J, Chan CHT, et al
    Assessment of PARP4 as a candidate breast cancer susceptibility gene.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05286.
    PubMed     Text format     Abstract available


  289. AL-HILLI Z, Choong G, Keeney MG, Visscher DW, et al
    Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05264.
    PubMed     Text format     Abstract available


  290. HEDRICK E, Li X, Cheng Y, Lacey A, et al
    Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05279.
    PubMed     Text format     Abstract available


  291. TURKKI R, Byckhov D, Lundin M, Isola J, et al
    Breast cancer outcome prediction with tumour tissue images and machine learning.
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05281.
    PubMed     Text format     Abstract available


  292. POMPONIO MK, Keele LJ, Fox KR, Clark AS, et al
    Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?
    Breast Cancer Res Treat. 2019 May 22. pii: 10.1007/s10549-019-05282.
    PubMed     Text format     Abstract available


  293. DECKER T, Marschner N, Muendlein A, Welt A, et al
    VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer.
    Breast Cancer Res Treat. 2019 May 21. pii: 10.1007/s10549-019-05280.
    PubMed     Text format     Abstract available


  294. JONGEN L, Floris G, Wildiers H, Claessens F, et al
    Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 May 20. pii: 10.1007/s10549-019-05252.
    PubMed     Text format     Abstract available


  295. ZHANG JY, Liao YH, Lin Y, Liu Q, et al
    Effects of tea consumption and the interactions with lipids on breast cancer survival.
    Breast Cancer Res Treat. 2019 May 16. pii: 10.1007/s10549-019-05253.
    PubMed     Text format     Abstract available


  296. SILBERHOLZ J, Bertsimas D, Vahdat L
    Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 May 14. pii: 10.1007/s10549-019-05208.
    PubMed     Text format     Abstract available


  297. PILEVARZADEH M, Amirshahi M, Afsargharehbagh R, Rafiemanesh H, et al
    Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 May 13. pii: 10.1007/s10549-019-05271.
    PubMed     Text format     Abstract available


  298. LI YR, Ro V, Steel L, Carrigan E, et al
    Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer.
    Breast Cancer Res Treat. 2019 May 13. pii: 10.1007/s10549-019-05267.
    PubMed     Text format     Abstract available


  299. AWAN AA, Hutton B, Hilton J, Mazzarello S, et al
    De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 May 11. pii: 10.1007/s10549-019-05265.
    PubMed     Text format     Abstract available


  300. SHENG JY, Blackford AL, Bardia A, Venkat R, et al
    Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2019 May 11. pii: 10.1007/s10549-019-05270.
    PubMed     Text format     Abstract available


  301. GOLDBERG M, Sutradhar R, Paszat L, Whelan TJ, et al
    Patterns of adjuvant care and outcomes of elderly women with stage I breast cancer after breast-conserving surgery: a population-based analysis.
    Breast Cancer Res Treat. 2019 May 10. pii: 10.1007/s10549-019-05266.
    PubMed     Text format     Abstract available


  302. AZRAD M, Blair CK, Rock CL, Sedjo RL, et al
    Adult weight gain accelerates the onset of breast cancer.
    Breast Cancer Res Treat. 2019 May 9. pii: 10.1007/s10549-019-05268.
    PubMed     Text format     Abstract available


  303. MORI H, Kubo M, Kai M, Yamada M, et al
    T-bet(+) lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 May 8. pii: 10.1007/s10549-019-05256.
    PubMed     Text format     Abstract available


  304. FONTAINE C, Renard V, Van den Bulk H, Vuylsteke P, et al
    Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
    Breast Cancer Res Treat. 2019 May 8. pii: 10.1007/s10549-019-05259.
    PubMed     Text format     Abstract available


  305. LUX MP, Bohme S, Hucherig S, Jeratsch U, et al
    Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
    Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05262.
    PubMed     Text format     Abstract available


  306. CAZZANIGA ME, Danesi R, Girmenia C, Invernizzi P, et al
    Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
    Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05261.
    PubMed     Text format     Abstract available


  307. AARTS BM, Klompenhouwer EG, Dresen RC, Laenen A, et al
    Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival.
    Breast Cancer Res Treat. 2019 May 7. pii: 10.1007/s10549-019-05254.
    PubMed     Text format     Abstract available


  308. COHEN EN, Fouad TM, Lee BN, Arun BK, et al
    Elevated serum levels of sialyl Lewis X (sLe(X)) and inflammatory mediators in patients with breast cancer.
    Breast Cancer Res Treat. 2019 May 3. pii: 10.1007/s10549-019-05258.
    PubMed     Text format     Abstract available


  309. IRENE SU H, Stark S, Kwan B, Boles S, et al
    Efficacy of a web-based women's health survivorship care plan for young breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 May 3. pii: 10.1007/s10549-019-05260.
    PubMed     Text format     Abstract available


  310. ELFGEN C, Montagna G, Schmid SM, Bierbauer W, et al
    Noncompliance with palliative systemic therapy in patients with distant metastatic breast cancer: a blind spot for oncologists?
    Breast Cancer Res Treat. 2019 May 2. pii: 10.1007/s10549-019-05255.
    PubMed     Text format     Abstract available


  311. SAVVA C, De Souza K, Ali R, Rakha EA, et al
    Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
    Breast Cancer Res Treat. 2019;175:105-115.
    PubMed     Text format     Abstract available


  312. JUNG J, Han W, Lee ES, Jung SY, et al
    Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
    Breast Cancer Res Treat. 2019;175:203-215.
    PubMed     Text format     Abstract available


    April 2019
  313. BAKER HA, Fabian CJ, Hastings RC, Dixon DA, et al
    Circulating adipose stromal cells as a response biomarker in phase II energy balance trials of obese breast cancer survivors and high-risk women.
    Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05251.
    PubMed     Text format     Abstract available


  314. WAGONER CW, Choi SK, Deal AM, Lee JT, et al
    Establishing physical activity in breast cancer: self-report versus activity tracker.
    Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05263.
    PubMed     Text format     Abstract available


  315. SESTAK I, Martin M, Dubsky P, Kronenwett R, et al
    Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
    Breast Cancer Res Treat. 2019 Apr 30. pii: 10.1007/s10549-019-05226.
    PubMed     Text format     Abstract available


  316. ACKLAND SP, Gebski V, Zdenkowski N, Wilson A, et al
    Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05187.
    PubMed     Text format     Abstract available


  317. TEYSIR J, Gegechkori N, Wisnivesky JP, Lin JJ, et al
    Racial disparities in surveillance mammography among older breast cancer survivors.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05250.
    PubMed     Text format     Abstract available


  318. KIM JY, Lee DW, Lee KH, Min A, et al
    Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05249.
    PubMed     Text format     Abstract available


  319. ROTTER J, Wilson L, Greiner MA, Pollack CE, et al
    Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
    Breast Cancer Res Treat. 2019 Apr 26. pii: 10.1007/s10549-019-05248.
    PubMed     Text format     Abstract available


  320. ABU-KHALAF MM, Safonov A, Stratton J, Wang S, et al
    Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.
    Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05178.
    PubMed     Text format     Abstract available


  321. LEE HM, Kim BW, Park S, Park S, et al
    Childbirth in young Korean women with previously treated breast cancer: The SMARTSHIP study.
    Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05244.
    PubMed     Text format     Abstract available


  322. WANG M, Chen H, Wu K, Ding A, et al
    Post-mastectomy immediate breast reconstruction is oncologically safe in well-selected T4 locally advanced breast cancer: a large population-based study and matched case-control analysis.
    Breast Cancer Res Treat. 2019 Apr 24. pii: 10.1007/s10549-019-05240.
    PubMed     Text format     Abstract available


  323. SAMBADE MJ, Prince G, Deal AM, Trembath D, et al
    Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.
    Breast Cancer Res Treat. 2019 Apr 23. pii: 10.1007/s10549-019-05211.
    PubMed     Text format     Abstract available


  324. ALTUNDAG K
    Oral or intravenous vinorelbine plus capecitabine in heavily pretreated HER2 negative metastatic breast cancer; similar effect or quality of life?
    Breast Cancer Res Treat. 2019 Apr 23. pii: 10.1007/s10549-019-05220.
    PubMed     Text format    


  325. SCHAIRER C, Hablas A, Eldein IAS, Gaafar R, et al
    Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.
    Breast Cancer Res Treat. 2019 Apr 22. pii: 10.1007/s10549-019-05237.
    PubMed     Text format     Abstract available


  326. GAO C, Yuan X, Jiang Z, Gan D, et al
    Regulation of AKT phosphorylation by GSK3beta and PTEN to control chemoresistance in breast cancer.
    Breast Cancer Res Treat. 2019 Apr 20. pii: 10.1007/s10549-019-05239.
    PubMed     Text format     Abstract available


  327. BELLON JR, Guo H, Barry WT, Dang CT, et al
    Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
    Breast Cancer Res Treat. 2019 Apr 19. pii: 10.1007/s10549-019-05238.
    PubMed     Text format     Abstract available


  328. BAHRI N, Fathi Najafi T, Homaei Shandiz F, Tohidinik HR, et al
    The relation between stressful life events and breast cancer: a systematic review and meta-analysis of cohort studies.
    Breast Cancer Res Treat. 2019 Apr 19. pii: 10.1007/s10549-019-05231.
    PubMed     Text format     Abstract available


  329. NOORDHOEK I, de Groot AF, Cohen D, Liefers GJ, et al
    Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05233.
    PubMed     Text format     Abstract available


  330. KHAN KA, Mazuquin B, Canaway A, Petrou S, et al
    Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05235.
    PubMed     Text format     Abstract available


  331. FLORES-DIAZ D, Arce C, Flores-Luna L, Reynoso-Noveron N, et al
    Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05234.
    PubMed     Text format     Abstract available


  332. MA X, Dang C, Min W, Diao Y, et al
    Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05189.
    PubMed     Text format     Abstract available


  333. LEE J, Lim B, Pearson T, Choi K, et al
    Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05218.
    PubMed     Text format     Abstract available


  334. CHEN BT, Jin T, Patel SK, Ye N, et al
    Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study.
    Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05230.
    PubMed     Text format     Abstract available


  335. CAGNEY DN, Lamba N, Montoya S, Li P, et al
    Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
    Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05236.
    PubMed     Text format     Abstract available


  336. DARCEY E, Lloyd R, Cadby G, Pilkington L, et al
    The association between mammographic density and breast cancer risk in Western Australian Aboriginal women.
    Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05225.
    PubMed     Text format     Abstract available


  337. BERNSTEIN-MOLHO R, Singer A, Laitman Y, Netzer I, et al
    Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
    Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05228.
    PubMed     Text format     Abstract available


  338. MUTONGA M, Speedy S, Rademaker A, Liu D, et al
    Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
    Breast Cancer Res Treat. 2019 Apr 11. pii: 10.1007/s10549-018-05088.
    PubMed     Text format     Abstract available


  339. VAN UDEN DJP, van Maaren MC, Bult P, Strobbe LJA, et al
    Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
    Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05219.
    PubMed     Text format     Abstract available


  340. NEUNER JM, Nattinger AB, Yen T, McGinley E, et al
    Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?
    Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05213.
    PubMed     Text format     Abstract available


  341. KREUTZ C, Schmidt ME, Steindorf K
    Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05217.
    PubMed     Text format     Abstract available


  342. HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
    Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
    Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05223.
    PubMed     Text format     Abstract available


  343. LU Y, Li J, Zhao X, Li J, et al
    Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm.
    Breast Cancer Res Treat. 2019 Apr 5. pii: 10.1007/s10549-019-05202.
    PubMed     Text format     Abstract available


  344. KUSAMA H, Shimoda M, Miyake T, Tanei T, et al
    Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues.
    Breast Cancer Res Treat. 2019 Apr 4. pii: 10.1007/s10549-019-05222.
    PubMed     Text format     Abstract available


  345. EVANS DGR, Harkness EF, Brentnall AR, van Veen EM, et al
    Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05210.
    PubMed     Text format     Abstract available


  346. KUROZUMI S, Joseph C, Raafat S, Sonbul S, et al
    Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05216.
    PubMed     Text format     Abstract available


  347. WANG G, Qin S, Zayas J, Ingle JN, et al
    4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05194.
    PubMed     Text format     Abstract available


  348. LIN Y, Wang C, Huang X, Zhou X, et al
    Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05207.
    PubMed     Text format     Abstract available


    March 2019
  349. KORZETS Y, Fyles A, Shepshelovich D, Amir E, et al
    Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Mar 30. pii: 10.1007/s10549-019-05209.
    PubMed     Text format     Abstract available


  350. DANIELL KM, Bardia A, Sun F, Roberts SA, et al
    Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Mar 27. pii: 10.1007/s10549-019-05206.
    PubMed     Text format     Abstract available


  351. AURIT SJ, Devesa SS, Soliman AS, Schairer C, et al
    Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015).
    Breast Cancer Res Treat. 2019 Mar 26. pii: 10.1007/s10549-019-05193.
    PubMed     Text format     Abstract available


  352. TORRES A, Ramdial JL, Aguirre LE, Mahtani R, et al
    Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05203.
    PubMed     Text format     Abstract available


  353. CAMARA RJA, Schwentner L, Friedl TWP, Deniz M, et al
    Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
    Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05171.
    PubMed     Text format     Abstract available


  354. CAO W, Xie Y, He Y, Li J, et al
    Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05199.
    PubMed     Text format     Abstract available


  355. VARELLA L, Eziokwu AS, Jia X, Kruse M, et al
    Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05176.
    PubMed     Text format     Abstract available


  356. HOSIO M, Urpilainen E, Marttila M, Hautakoski A, et al
    Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05185.
    PubMed     Text format     Abstract available


  357. DAVIS LE, Fulton C, Bubis LD, Sussman J, et al
    Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.
    Breast Cancer Res Treat. 2019 Mar 16. pii: 10.1007/s10549-019-05196.
    PubMed     Text format     Abstract available


  358. HOLM-RASMUSSEN EV, Jensen MB, Balslev E, Kroman N, et al
    Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.
    Breast Cancer Res Treat. 2019 Mar 14. pii: 10.1007/s10549-019-05200.
    PubMed     Text format     Abstract available


  359. YU C, Qin N, Pu Z, Song C, et al
    Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05177.
    PubMed     Text format     Abstract available


  360. MARSCHNER N, Trarbach T, Rauh J, Meyer D, et al
    Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05197.
    PubMed     Text format     Abstract available


  361. DE GROOT AF, Blok EJ, Charehbili A, Engels CC, et al
    Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05195.
    PubMed     Text format     Abstract available


  362. FASCHING PA, Gass P, Haberle L, Volz B, et al
    Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05198.
    PubMed     Text format     Abstract available


  363. TIAN J, Chen X, Fu S, Zhang R, et al
    Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05183.
    PubMed     Text format     Abstract available


  364. LYNCE F, Barac A, Geng X, Dang C, et al
    Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05191.
    PubMed     Text format     Abstract available


  365. CHRISCHILLES EA, Riley D, Letuchy E, Koehler L, et al
    Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05184.
    PubMed     Text format     Abstract available


  366. ZHANG B, Long EF
    Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05190.
    PubMed     Text format     Abstract available


  367. PLAVC G, Ratosa I, Zagar T, Zadnik V, et al
    Explaining variation in quality of breast cancer care and its impact: a nationwide population-based study from Slovenia.
    Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05186.
    PubMed     Text format     Abstract available


  368. KAISER K, Cameron KA, Beaumont J, Garcia SF, et al
    What does risk of future cancer mean to breast cancer patients?
    Breast Cancer Res Treat. 2019 Mar 6. pii: 10.1007/s10549-019-05182.
    PubMed     Text format     Abstract available


  369. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    ERalpha upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-kappaB in breast cancer.
    Breast Cancer Res Treat. 2019 Mar 4. pii: 10.1007/s10549-018-05108.
    PubMed     Text format     Abstract available


  370. DOEGE D, Thong MS, Koch-Gallenkamp L, Bertram H, et al
    Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany.
    Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05188.
    PubMed     Text format     Abstract available


  371. LEE J, Lim B, Pearson T, Choi K, et al
    Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05166.
    PubMed     Text format     Abstract available


  372. VAN DOOIJEWEERT C, Deckers IAG, Baas IO, van der Wall E, et al
    Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
    Breast Cancer Res Treat. 2019 Mar 1. pii: 10.1007/s10549-019-05180.
    PubMed     Text format     Abstract available


    February 2019
  373. AFZALI F, Akbari P, Naderi-Manesh H, Gardaneh M, et al
    The next generation personalized models to screen hidden layers of breast cancer tumorigenicity.
    Breast Cancer Res Treat. 2019 Feb 27. pii: 10.1007/s10549-019-05159.
    PubMed     Text format     Abstract available


  374. MARKS DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, et al
    The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05169.
    PubMed     Text format     Abstract available


  375. SAGAWA N, Ohno S, Hiratsuka T, Kondo N, et al
    The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05164.
    PubMed     Text format     Abstract available


  376. RICE SR, Feigenberg SJ, Hamza M, Molitoris JK, et al
    Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05150.
    PubMed     Text format     Abstract available


  377. ACETO GM, Awadelkarim KD, Di Nicola M, Moscatello C, et al
    Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05168.
    PubMed     Text format     Abstract available


  378. TICE JA, Bissell MCS, Miglioretti DL, Gard CC, et al
    Validation of the breast cancer surveillance consortium model of breast cancer risk.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05167.
    PubMed     Text format     Abstract available


  379. WUERSTLEIN R, Kates R, Gluz O, Grischke EM, et al
    Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-018-05075.
    PubMed     Text format     Abstract available


  380. GUO L, Chen G, Zhang W, Zhou L, et al
    A high-risk luminal A dominant breast cancer subtype with increased mobility.
    Breast Cancer Res Treat. 2019 Feb 19. pii: 10.1007/s10549-019-05135.
    PubMed     Text format     Abstract available


  381. ZHAO H, Shen J, Moore SC, Ye Y, et al
    Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
    Breast Cancer Res Treat. 2019 Feb 15. pii: 10.1007/s10549-019-05165.
    PubMed     Text format     Abstract available


  382. KOTSOPOULOS J, Lubinski J, Lynch HT, Tung N, et al
    Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05162.
    PubMed     Text format     Abstract available


  383. STAVRAKA C, Pouptsis A, Okonta L, DeSouza K, et al
    Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05144.
    PubMed     Text format     Abstract available


  384. GREGOROWITSCH ML, Ghedri A, Young-Afat DA, Bijlsma R, et al
    The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05149.
    PubMed     Text format     Abstract available


  385. YANG SX, Polley EC
    Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05142.
    PubMed     Text format     Abstract available


  386. LAN Y, Zhao E, Luo S, Xiao Y, et al
    Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
    Breast Cancer Res Treat. 2019 Feb 9. pii: 10.1007/s10549-019-05153.
    PubMed     Text format     Abstract available


  387. O'MEARA T, Safonov A, Casadevall D, Qing T, et al
    Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05156.
    PubMed     Text format     Abstract available


  388. BICK U, Engel C, Krug B, Heindel W, et al
    High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05152.
    PubMed     Text format     Abstract available


  389. LIU Y, Pandey PR, Sharma S, Xing F, et al
    ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-018-05126.
    PubMed     Text format     Abstract available


  390. HUSSAIN Y, Drill E, Dang CT, Liu JE, et al
    Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05139.
    PubMed     Text format     Abstract available


  391. DICKINSON SL, Golzarri-Arroyo L, Brown AW, McComb B, et al
    Change in study randomization allocation needs to be included in statistical analysis: comment on 'Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEA
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05155.
    PubMed     Text format    


  392. SUN M, Wu D, Zhou K, Li H, et al
    An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Breast Cancer Res Treat. 2019 Feb 4. pii: 10.1007/s10549-019-05147.
    PubMed     Text format     Abstract available


  393. LIGABUE MB, Campanini I, Veroni P, Cepelli A, et al
    Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05136.
    PubMed     Text format     Abstract available


  394. LIU ZH, Wang K, Lin DY, Xu J, et al
    Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05148.
    PubMed     Text format     Abstract available


  395. ALTUNDAG K
    HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.
    Breast Cancer Res Treat. 2019 Feb 1. pii: 10.1007/s10549-019-05151.
    PubMed     Text format    


  396. ESEN E, Aslan M, Sonbahar BC, Kerimoglu RS, et al
    YouTube English videos as a source of information on breast self-examination.
    Breast Cancer Res Treat. 2019;173:629-635.
    PubMed     Text format     Abstract available


  397. SILVER MI, Klein W, Samimi G, Minasian L, et al
    Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study((R)).
    Breast Cancer Res Treat. 2019;173:719-726.
    PubMed     Text format     Abstract available


  398. HEINEY SP, Parker PD, Felder TM, Adams SA, et al
    A systematic review of interventions to improve adherence to endocrine therapy.
    Breast Cancer Res Treat. 2019;173:499-510.
    PubMed     Text format     Abstract available


    January 2019
  399. FATEHI S, Maasoumi R, Atashsokhan G, Hamidzadeh A, et al
    The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 Jan 30. pii: 10.1007/s10549-019-05140.
    PubMed     Text format     Abstract available


  400. SZIJGYARTO Z, Flach KD, Opdam M, Palmieri C, et al
    Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
    Breast Cancer Res Treat. 2019 Jan 24. pii: 10.1007/s10549-018-05110.
    PubMed     Text format     Abstract available


  401. CAMP NJ, Madsen MJ, Herranz J, Rodriguez-Lescure A, et al
    Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 23. pii: 10.1007/s10549-018-05097.
    PubMed     Text format     Abstract available


  402. SUH KJ, Ryu HS, Lee KH, Kim H, et al
    Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-019-05128.
    PubMed     Text format     Abstract available


  403. EL-ANSARI R, Craze ML, Alfarsi L, Soria D, et al
    The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-018-05111.
    PubMed     Text format     Abstract available


  404. WEISS A, Grossmith S, Cutts D, Mikami SA, et al
    Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05116.
    PubMed     Text format     Abstract available


  405. COOPEY SB, Kartal K, Li C, Yala A, et al
    Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05117.
    PubMed     Text format     Abstract available


  406. ROBERTSON S, Ronnlund C, de Boniface J, Hartman J, et al
    Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05119.
    PubMed     Text format     Abstract available


  407. PETRELLI F, Ghidini A, Pedersini R, Cabiddu M, et al
    Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-019-05133.
    PubMed     Text format     Abstract available


  408. XU X, Chlebowski RT, Shi J, Barac A, et al
    Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05086.
    PubMed     Text format     Abstract available


  409. BATTISTI NML, Kingston B, King J, Denton A, et al
    Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Breast Cancer Res Treat. 2019 Jan 17. pii: 10.1007/s10549-019-05134.
    PubMed     Text format     Abstract available


  410. FRIEDLAENDER A, Vuilleumier A, Viassolo V, Ayme A, et al
    BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 11. pii: 10.1007/s10549-018-05127.
    PubMed     Text format     Abstract available


  411. RUGO HS, Finn RS, Dieras V, Ettl J, et al
    Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05125.
    PubMed     Text format     Abstract available


  412. HASHEMI SM, Balouchi A, Al-Mawali A, Rafiemanesh H, et al
    Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05131.
    PubMed     Text format     Abstract available


  413. GADALLA R, Hassan H, Ibrahim SA, Abdullah MS, et al
    Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05129.
    PubMed     Text format     Abstract available


  414. NITZ U, Gluz O, Christgen M, Kates RE, et al
    Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05105.
    PubMed     Text format     Abstract available


  415. STOVGAARD ES, Dyhl-Polk A, Roslind A, Balslev E, et al
    PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05130.
    PubMed     Text format     Abstract available


  416. LUBINSKI J, Huzarski T, Gronwald J, Cybulski C, et al
    Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
    Breast Cancer Res Treat. 2019 Jan 5. pii: 10.1007/s10549-018-05076.
    PubMed     Text format     Abstract available


  417. ALHUDIRI IM, Nolan CC, Ellis IO, Elzagheid A, et al
    Expression of Lamin A/C in early-stage breast cancer and its prognostic value.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05092.
    PubMed     Text format     Abstract available


  418. VANE MLG, Willemsen MA, van Roozendaal LM, van Kuijk SMJ, et al
    Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05074.
    PubMed     Text format     Abstract available


  419. BOWDEN AR, Tischkowitz M
    Clinical implications of germline mutations in breast cancer genes: RECQL.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05096.
    PubMed     Text format     Abstract available


  420. CHENG ES, Yu XQ
    Re: The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. Sep 2018;171(2):477-488.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05101.
    PubMed     Text format    


  421. AUSTIN AM, Kapadia NS, Brooks GA, Onega TL, et al
    Comparison of treatment of early-stage breast cancer among Nurses' Health Study participants and other Medicare beneficiaries.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05098.
    PubMed     Text format     Abstract available


  422. YAMAMOTO T, Kanaya N, Somlo G, Chen S, et al
    Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05104.
    PubMed     Text format     Abstract available


  423. YANG Z, Ouyang T, Li J, Wang T, et al
    Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05124.
    PubMed     Text format     Abstract available


  424. LUSTIG DB, Warburton R, Dingee CK, Kuusk U, et al
    Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05109.
    PubMed     Text format     Abstract available


  425. OCANA A, Gil-Martin M, Antolin S, Atienza M, et al
    Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05100.
    PubMed     Text format     Abstract available


  426. KENSLER KH, Eliassen AH, Rosner BA, Hankinson SE, et al
    Pre-diagnostic sex hormone levels and survival among breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05121.
    PubMed     Text format     Abstract available


  427. PATEL DA, Xi J, Luo J, Hassan B, et al
    Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05106.
    PubMed     Text format     Abstract available


  428. O'BRIEN P, Matheson K, Jeyakumar A, Anderson K, et al
    The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05114.
    PubMed     Text format     Abstract available


  429. KIM SJ, Zhang CXW, Demsky R, Armel S, et al
    Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05118.
    PubMed     Text format     Abstract available


  430. CARUANA E, Foucher Y, Tessier P, Frenel JS, et al
    Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05107.
    PubMed     Text format     Abstract available


  431. WUNDERLE M, Pretscher J, Brucker SY, Volz B, et al
    Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05115.
    PubMed     Text format     Abstract available


  432. GOGATE A, Rotter JS, Trogdon JG, Meng K, et al
    An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05099.
    PubMed     Text format     Abstract available


  433. HU J, Wang X, Guo S, Chen F, et al
    Peer support interventions for breast cancer patients: a systematic review.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-5033.
    PubMed     Text format     Abstract available


    December 2018
  434. LYES MA, Payne S, Ferrell P, Pizzo SV, et al
    Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence.
    Breast Cancer Res Treat. 2018 Dec 29. pii: 10.1007/s10549-018-05103.
    PubMed     Text format     Abstract available


  435. THEBERGE I, Vandal N, Guertin MH, Perron L, et al
    The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
    Breast Cancer Res Treat. 2018 Dec 18. pii: 10.1007/s10549-018-05095.
    PubMed     Text format     Abstract available


  436. MALMGREN J, Hurlbert M, Atwood M, Kaplan HG, et al
    Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05090.
    PubMed     Text format     Abstract available


  437. BUTTON B, Croessmann S, Chu D, Rosen DM, et al
    The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05087.
    PubMed     Text format     Abstract available


  438. KIM JH, Yoon KH, Hur H, Park S, et al
    Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05091.
    PubMed     Text format     Abstract available


  439. JOSEPH C, Arshad M, Kurozomi S, Althobiti M, et al
    Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
    Breast Cancer Res Treat. 2018 Dec 15. pii: 10.1007/s10549-018-05085.
    PubMed     Text format     Abstract available


  440. JOHANSSON ALV, Weibull CE, Fredriksson I, Lambe M, et al
    Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05083.
    PubMed     Text format     Abstract available


  441. DURAN-LOZANO L, Montalban G, Bonache S, Moles-Fernandez A, et al
    Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05094.
    PubMed     Text format     Abstract available


  442. RAGHAVENDRA A, Wecsler J, Ji L, Sheth P, et al
    Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    Breast Cancer Res Treat. 2018 Dec 12. pii: 10.1007/s10549-018-05084.
    PubMed     Text format     Abstract available


  443. WANG XM, Zhang Z, Pan LH, Cao XC, et al
    KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Breast Cancer Res Treat. 2018 Dec 8. pii: 10.1007/s10549-018-05069.
    PubMed     Text format     Abstract available


  444. NANNI O, Amadori D, De Censi A, Rocca A, et al
    Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
    Breast Cancer Res Treat. 2018 Dec 7. pii: 10.1007/s10549-018-05070.
    PubMed     Text format     Abstract available


  445. PARANJPE R, John G, Trivedi M, Abughosh S, et al
    Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
    Breast Cancer Res Treat. 2018 Dec 6. pii: 10.1007/s10549-018-05073.
    PubMed     Text format     Abstract available


  446. DONENBERG T, George S, Ali J, Bravo G, et al
    A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Breast Cancer Res Treat. 2018 Dec 4. pii: 10.1007/s10549-018-5045.
    PubMed     Text format     Abstract available


  447. COUGHLIN SS, Paxton RJ, Moore N, Stewart JL, et al
    Survivorship issues in older breast cancer survivors.
    Breast Cancer Res Treat. 2018 Dec 1. pii: 10.1007/s10549-018-05078.
    PubMed     Text format     Abstract available


  448. MCCLATCHY DM 3RD, Zuurbier RA, Wells WA, Paulsen KD, et al
    Micro-computed tomography enables rapid surgical margin assessment during breast conserving surgery (BCS): correlation of whole BCS micro-CT readings to final histopathology.
    Breast Cancer Res Treat. 2018;172:587-595.
    PubMed     Text format     Abstract available


  449. MCMULLEN ER, Gonzalez ME, Skala SL, Tran M, et al
    CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast.
    Breast Cancer Res Treat. 2018;172:577-586.
    PubMed     Text format     Abstract available


    November 2018
  450. LIDBRINK E, Chmielowska E, Otremba B, Bouhlel A, et al
    A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
    Breast Cancer Res Treat. 2018 Nov 30. pii: 10.1007/s10549-018-5058.
    PubMed     Text format     Abstract available


  451. WALSH EM, Shalaby A, O'Loughlin M, Keane N, et al
    Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Breast Cancer Res Treat. 2018 Nov 28. pii: 10.1007/s10549-018-5066.
    PubMed     Text format     Abstract available


  452. HOLLERN DP, Contreras CM, Dance-Barnes S, Silva GO, et al
    A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5061.
    PubMed     Text format     Abstract available


  453. SHTAM T, Naryzhny S, Samsonov R, Karasik D, et al
    Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5043.
    PubMed     Text format     Abstract available


  454. ABOUEGYLAH M, Braunstein LZ, Alm El-Din MA, Niemierko A, et al
    Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5053.
    PubMed     Text format     Abstract available


  455. GIBBS LD, Chaudhary P, Mansheim K, Hare RJ, et al
    ANXA2 expression in African American triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5030.
    PubMed     Text format     Abstract available


  456. IGNATOV T, Claus M, Nass N, Haybaeck J, et al
    G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5064.
    PubMed     Text format     Abstract available


  457. CHASAMPALIOTI M, Green AR, Ellis IO, Rakha EA, et al
    Connexin 43 is an independent predictor of patient outcome in breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5063.
    PubMed     Text format     Abstract available


  458. HENRY DA, Lee MC, Almanza D, Ahmed KA, et al
    Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5057.
    PubMed     Text format     Abstract available


  459. CRAZE ML, El-Ansari R, Aleskandarany MA, Cheng KW, et al
    Glutamate dehydrogenase (GLUD1) expression in breast cancer.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5060.
    PubMed     Text format     Abstract available


  460. LOO LWM, Gao C, Shvetsov YB, Okoro DR, et al
    MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5065.
    PubMed     Text format     Abstract available


  461. WANG J, Xu B, Wang W, Zhai X, et al
    Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5047.
    PubMed     Text format     Abstract available


  462. ROZNER RN, Freites-Martinez A, Shapiro J, Geer EB, et al
    Safety of 5alpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
    Breast Cancer Res Treat. 2018 Nov 22. pii: 10.1007/s10549-018-4996.
    PubMed     Text format     Abstract available


  463. DIBABA DT, Ogunsina K, Braithwaite D, Akinyemiju T, et al
    Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5056.
    PubMed     Text format     Abstract available


  464. HASKINS CB, McDowell BD, Carnahan RM, Fiedorowicz JG, et al
    Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5050.
    PubMed     Text format     Abstract available


  465. CAPARICA R, Bruzzone M, Poggio F, Ceppi M, et al
    Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5055.
    PubMed     Text format     Abstract available


  466. ZOOROB RJ, Salemi JL, Mejia de Grubb MC, Modak S, et al
    A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5059.
    PubMed     Text format     Abstract available


  467. LEE KWC, Lord S, Finn RS, Lim E, et al
    The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5054.
    PubMed     Text format     Abstract available


  468. CAO J, Eshak ES, Liu K, Muraki I, et al
    Sleep duration and risk of breast cancer: The JACC Study.
    Breast Cancer Res Treat. 2018 Nov 20. pii: 10.1007/s10549-018-4995.
    PubMed     Text format     Abstract available


  469. JONGEN L, Floris G, Boeckx B, Smeets D, et al
    Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
    Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5049.
    PubMed     Text format     Abstract available


  470. LIU J, Liu L, Yague E, Yang Q, et al
    GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
    Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5052.
    PubMed     Text format     Abstract available


  471. CORSO G, Pravettoni G, Galimberti V, Veronesi P, et al
    Clinical implication of E-cadherin deficiency in lobular breast cancer.
    Breast Cancer Res Treat. 2018 Nov 17. pii: 10.1007/s10549-018-5051.
    PubMed     Text format    


  472. XU R, Tang P, Li C
    Association between pre-operative magnetic resonance imaging (MRI) and surgical outcomes in breast cancer: not yet determined.
    Breast Cancer Res Treat. 2018 Nov 16. pii: 10.1007/s10549-018-5010.
    PubMed     Text format    


  473. BLEICHER RJ, Chang C, Wang CE, Goldstein LJ, et al
    Treatment delays from transfers of care and their impact on breast cancer quality measures.
    Breast Cancer Res Treat. 2018 Nov 15. pii: 10.1007/s10549-018-5046.
    PubMed     Text format     Abstract available


  474. MORTEN BC, Chiu S, Oldmeadow C, Lubinski J, et al
    The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Nov 14. pii: 10.1007/s10549-018-5039.
    PubMed     Text format     Abstract available


  475. DESANTIS CE, Ma J, Jemal A
    Trends in stage at diagnosis for young breast cancer patients in the United States.
    Breast Cancer Res Treat. 2018 Nov 13. pii: 10.1007/s10549-018-5042.
    PubMed     Text format     Abstract available


  476. KIM YH, Hwang JH, Bae JH, Choi JY, et al
    Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy.
    Breast Cancer Res Treat. 2018 Nov 12. pii: 10.1007/s10549-018-5041.
    PubMed     Text format     Abstract available


  477. DROGEMOLLER BI, Wright GEB, Shih J, Monzon JG, et al
    CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
    Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5027.
    PubMed     Text format     Abstract available


  478. BUSCARIOLLO DL, Cronin AM, Borstelmann NA, Punglia RS, et al
    Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women.
    Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5006.
    PubMed     Text format     Abstract available


  479. GUDINA AT, Copeland G, Soliman AS, Hirko KA, et al
    Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.
    Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5037.
    PubMed     Text format     Abstract available


  480. SKULI SJ, Sheng JY, Bantug ET, Zafman N, et al
    Survivorship care visits in a high-risk population of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5028.
    PubMed     Text format     Abstract available


  481. XUE C, Wei W, Sun P, Zheng W, et al
    Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-4997.
    PubMed     Text format     Abstract available


  482. HOPPE EJ, Hussain LR, Grannan KJ, Dunki-Jacobs EM, et al
    Racial disparities in breast cancer persist despite early detection: analysis of treatment of stage 1 breast cancer and effect of insurance status on disparities.
    Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-5036.
    PubMed     Text format     Abstract available


  483. LI T, Yang J, Lv Y, Yin F, et al
    Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer.
    Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5029.
    PubMed     Text format     Abstract available


  484. PARK S, Moon BI, Oh SJ, Lee HB, et al
    Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5032.
    PubMed     Text format     Abstract available


  485. HENG YJ, Wang J, Ahearn TU, Brown SB, et al
    Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.
    Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5034.
    PubMed     Text format     Abstract available


  486. SZOSTAKOWSKA M, Trebinska-Stryjewska A, Grzybowska EA, Fabisiewicz A, et al
    Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
    Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5023.
    PubMed     Text format     Abstract available


  487. SUNG JS, Corben AD, Brooks JD, Edelweiss M, et al
    Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
    Breast Cancer Res Treat. 2018;172:487-496.
    PubMed     Text format     Abstract available


  488. NARAYAN AK, Elkin EB, Lehman CD, Morris EA, et al
    Quantifying performance thresholds for recommending screening mammography: a revealed preference analysis of USPSTF guidelines.
    Breast Cancer Res Treat. 2018;172:463-468.
    PubMed     Text format     Abstract available


  489. SANCHEZ-SPITMAN AB, Dezentje VO, Swen JJ, Moes DJAR, et al
    Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
    Breast Cancer Res Treat. 2018;172:401-411.
    PubMed     Text format     Abstract available


  490. WU NC, Wong W, Ho KE, Chu VC, et al
    Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Breast Cancer Res Treat. 2018;172:327-338.
    PubMed     Text format     Abstract available


  491. REGMI S, Fung TS, Lim S, Luo KQ, et al
    Fluidic shear stress increases the anti-cancer effects of ROS-generating drugs in circulating tumor cells.
    Breast Cancer Res Treat. 2018;172:297-312.
    PubMed     Text format     Abstract available


  492. TUDINI E, Moghadasi S, Parsons MT, van der Kolk L, et al
    Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
    Breast Cancer Res Treat. 2018;172:497-503.
    PubMed     Text format     Abstract available


  493. YEAP PM, Evans A, Purdie CA, Jordan LB, et al
    A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma.
    Breast Cancer Res Treat. 2018;172:381-389.
    PubMed     Text format     Abstract available


  494. PAREKH A, Fu W, Hu C, Shen CJ, et al
    Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database.
    Breast Cancer Res Treat. 2018;172:201-208.
    PubMed     Text format     Abstract available


  495. ALSHAKER H, Srivats S, Monteil D, Wang Q, et al
    Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
    Breast Cancer Res Treat. 2018;172:33-43.
    PubMed     Text format     Abstract available


  496. BARNES-KEDAR I, Bernstein-Molho R, Ginzach N, Hartmajer S, et al
    The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Breast Cancer Res Treat. 2018;172:151-157.
    PubMed     Text format     Abstract available


    October 2018
  497. YOON TI, Kwak BS, Yi OV, Kim S, et al
    Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
    Breast Cancer Res Treat. 2018 Oct 30. pii: 10.1007/s10549-018-5031.
    PubMed     Text format     Abstract available


  498. VALLET S, Fan F, Malvestiti S, Pecherstorfer M, et al
    Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Breast Cancer Res Treat. 2018 Oct 29. pii: 10.1007/s10549-018-5022.
    PubMed     Text format     Abstract available


  499. RODRIGUES-FERREIRA S, Nehlig A, Monchecourt C, Nasr S, et al
    Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5026.
    PubMed     Text format     Abstract available


  500. CAO S, Zhou J, Zhu Z, Wei F, et al
    Adult weight change and the risk of pre- and postmenopausal breast cancer in the Chinese Wuxi Exposure and Breast Cancer Study.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5016.
    PubMed     Text format     Abstract available


  501. WALTER KR, Ford ME, Gregoski MJ, Kramer RM, et al
    Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-4992.
    PubMed     Text format     Abstract available


  502. MASKARINEC G, Shvetsov YB, Conroy SM, Haiman CA, et al
    Type 2 diabetes as a predictor of survival among breast cancer patients: the multiethnic cohort.
    Breast Cancer Res Treat. 2018 Oct 26. pii: 10.1007/s10549-018-5025.
    PubMed     Text format     Abstract available


  503. LIU GY, Li JW, Zuo WJ, Ivanova D, et al
    Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5024.
    PubMed     Text format     Abstract available


  504. OHARA AM, Naoi Y, Shimazu K, Kagara N, et al
    PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5020.
    PubMed     Text format     Abstract available


  505. JONCZYK MM, Jean J, Graham R, Chatterjee A, et al
    Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5018.
    PubMed     Text format     Abstract available


  506. CABEL L, Carton M, Cheaib B, Pierga JY, et al
    Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
    Breast Cancer Res Treat. 2018 Oct 24. pii: 10.1007/s10549-018-5017.
    PubMed     Text format     Abstract available


  507. VAN DEN BERG MMGA, Kok DE, Posthuma L, Kamps L, et al
    Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 23. pii: 10.1007/s10549-018-5014.
    PubMed     Text format     Abstract available


  508. JEREVALL PL, Brock J, Palazzo J, Wieczorek T, et al
    Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5013.
    PubMed     Text format     Abstract available


  509. RYU JM, Choi HJ, Kim I, Nam SJ, et al
    Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5015.
    PubMed     Text format     Abstract available


  510. BLANCO C, Markowitz JC, Hellerstein DJ, Nezu AM, et al
    A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4994.
    PubMed     Text format     Abstract available


  511. WU T, Sultan LR, Tian J, Cary TW, et al
    Machine learning for diagnostic ultrasound of triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4984.
    PubMed     Text format     Abstract available


  512. ALTUNDAG K
    Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-5019.
    PubMed     Text format    


  513. HE X, Ji J, Dong R, Liu H, et al
    Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    Breast Cancer Res Treat. 2018 Oct 19. pii: 10.1007/s10549-018-5005.
    PubMed     Text format     Abstract available


  514. SOPIK V, Sun P, Narod SA
    Predictors of time to death after distant recurrence in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5002.
    PubMed     Text format     Abstract available


  515. LEONARDIS JM, Diefenbach BJ, Lyons DA, Olinger TA, et al
    The influence of reconstruction choice and inclusion of radiation therapy on functional shoulder biomechanics in women undergoing mastectomy for breast cancer.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5003.
    PubMed     Text format     Abstract available


  516. CAIN EH, Saha A, Harowicz MR, Marks JR, et al
    Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-4990.
    PubMed     Text format     Abstract available


  517. FASCHING PA, Hartkopf AD, Gass P, Haberle L, et al
    Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5008.
    PubMed     Text format     Abstract available


  518. ALTUNDAG K
    Better pathological tumor characteristics might occur in recurrent metastatic breast cancer patients after 10-year metastatic free interval.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5011.
    PubMed     Text format    


  519. HWANG HW, Jung H, Hyeon J, Park YH, et al
    A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4981.
    PubMed     Text format     Abstract available


  520. TERADA M
    Challenge for identifying the origin of occult breast cancer for optimizing local therapy.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4931.
    PubMed     Text format    


  521. INNO A, Barni S, Ghidini A, Zaniboni A, et al
    One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-5001.
    PubMed     Text format     Abstract available


  522. ASTASHCHANKA A, Shroka TM, Jacobsen BM
    Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-4989.
    PubMed     Text format     Abstract available


  523. HENNIGS A, Kopke M, Feisst M, Riedel F, et al
    Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Breast Cancer Res Treat. 2018 Oct 12. pii: 10.1007/s10549-018-5009.
    PubMed     Text format     Abstract available


  524. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2018 Oct 11. pii: 10.1007/s10549-018-4975.
    PubMed     Text format     Abstract available


  525. GUESTINI F, Ono K, Miyashita M, Ishida T, et al
    Impact of Topoisomerase IIalpha, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4985.
    PubMed     Text format     Abstract available


  526. ALFARSI LH, Elansari R, Toss MS, Diez-Rodriguez M, et al
    Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4978.
    PubMed     Text format     Abstract available


  527. KUSSAIBI H, Alkharsah KR, Altamimi D, Alsayyah A, et al
    Alternative splicing is an important mechanism behind KAI1 loss of function in breast cancer patients from Saudi Arabia.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4999.
    PubMed     Text format     Abstract available


  528. KRAMER CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, et al
    The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review.
    Breast Cancer Res Treat. 2018 Oct 9. pii: 10.1007/s10549-018-4987.
    PubMed     Text format     Abstract available


  529. REN JX, Gong Y, Ling H, Hu X, et al
    Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics.
    Breast Cancer Res Treat. 2018 Oct 6. pii: 10.1007/s10549-018-4956.
    PubMed     Text format     Abstract available


  530. JAUCH SF, Riethdorf S, Sprick MR, Schutz F, et al
    Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Oct 1. pii: 10.1007/s10549-018-4972.
    PubMed     Text format     Abstract available


  531. JANSEN LE, Teft WA, Rose RV, Lizotte DJ, et al
    CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
    Breast Cancer Res Treat. 2018;171:701-708.
    PubMed     Text format     Abstract available


  532. LURASCHI R, Lazzari R, Galimberti V, Rondi E, et al
    Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED).
    Breast Cancer Res Treat. 2018;171:693-699.
    PubMed     Text format     Abstract available


  533. COELHO BA, Paiva SPC, da Silva Filho AL
    Extremely brief mindfulness interventions for women undergoing breast biopsies: a randomized controlled trial.
    Breast Cancer Res Treat. 2018;171:685-692.
    PubMed     Text format     Abstract available


  534. EULER-CHELPIN MV, Lillholm M, Napolitano G, Vejborg I, et al
    Screening mammography: benefit of double reading by breast density.
    Breast Cancer Res Treat. 2018;171:767-776.
    PubMed     Text format     Abstract available


    September 2018
  535. GUCALP A, Traina TA, Eisner JR, Parker JS, et al
    Male breast cancer: a disease distinct from female breast cancer.
    Breast Cancer Res Treat. 2018 Sep 28. pii: 10.1007/s10549-018-4921.
    PubMed     Text format     Abstract available


  536. SIMONE BA, Ko K, Simone NL
    Re: Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2018 Sep 27. pii: 10.1007/s10549-018-4940.
    PubMed     Text format    


  537. ZUNIGA KE, Parma DL, Munoz E, Spaniol M, et al
    Dietary intervention among breast cancer survivors increased adherence to a Mediterranean-style, anti-inflammatory dietary pattern: the Rx for Better Breast Health Randomized Controlled Trial.
    Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4982.
    PubMed     Text format     Abstract available


  538. RESNICOW K, Patel MR, Mcleod MC, Katz SJ, et al
    Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty.
    Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4976.
    PubMed     Text format     Abstract available


  539. SMETANAY K, Junio P, Feisst M, Seitz J, et al
    COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2018 Sep 25. pii: 10.1007/s10549-018-4983.
    PubMed     Text format     Abstract available


  540. XU R, Zhu J
    Association between red and processed meat with breast cancer: Comment on "Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies" by Guo et al.
    Breast Cancer Res Treat. 2018 Sep 24. pii: 10.1007/s10549-018-4977.
    PubMed     Text format    


  541. BHARGAVA A, Saha S
    T-Type voltage gated calcium channels: a target in breast cancer?
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4970.
    PubMed     Text format     Abstract available


  542. SHEN Y, Fujii T, Ueno NT, Tripathy D, et al
    Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4969.
    PubMed     Text format     Abstract available


  543. IWATA H, Masuda N, Yamamoto Y, Fujisawa T, et al
    Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4964.
    PubMed     Text format     Abstract available


  544. CHANG E, Mougalian SS, Adelson KB, Young MR, et al
    Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4968.
    PubMed     Text format     Abstract available


  545. ACEVEDO F, Armengol VD, Deng Z, Tang R, et al
    Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4962.
    PubMed     Text format     Abstract available


  546. LEE SK, Kim SW, Yu JH, Lee JE, et al
    Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4947.
    PubMed     Text format     Abstract available


  547. HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
    Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4944.
    PubMed     Text format     Abstract available


  548. NIRAULA S, Gyawali B
    Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4967.
    PubMed     Text format     Abstract available


  549. TONG WL, Callahan BM, Tu YN, Zaman S, et al
    Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates.
    Breast Cancer Res Treat. 2018 Sep 18. pii: 10.1007/s10549-018-4961.
    PubMed     Text format     Abstract available


  550. FALATO C, Taylor SK, Szulkin R, Nordblom A, et al
    Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4936.
    PubMed     Text format     Abstract available


  551. LIU Z, Sahli Z, Wang Y, Wolff AC, et al
    Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4950.
    PubMed     Text format     Abstract available


  552. SPRING L, Niemierko A, Haddad S, Yuen M, et al
    Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
    Breast Cancer Res Treat. 2018 Sep 15. pii: 10.1007/s10549-018-4959.
    PubMed     Text format     Abstract available


  553. RYU JM, Choi HJ, Kim I, Lee SK, et al
    Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4948.
    PubMed     Text format     Abstract available


  554. KHALED H, Gamal H, Lotayef M, Knauer M, et al
    The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4945.
    PubMed     Text format     Abstract available


  555. OLIVA-MORENO J, Pena-Longobardo LM
    Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4963.
    PubMed     Text format     Abstract available


  556. JEON SH, Shin KH, Kim JH, Kim K, et al
    Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4966.
    PubMed     Text format     Abstract available


  557. PEREZ-PENA J, Gyorffy B, Amir E, Pandiella A, et al
    Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
    Breast Cancer Res Treat. 2018 Sep 11. pii: 10.1007/s10549-018-4965.
    PubMed     Text format     Abstract available


  558. TAKADA M, Sugimoto M, Masuda N, Iwata H, et al
    Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
    Breast Cancer Res Treat. 2018 Sep 7. pii: 10.1007/s10549-018-4958.
    PubMed     Text format     Abstract available


  559. FENTIMAN IS
    Surgical options for male breast cancer.
    Breast Cancer Res Treat. 2018 Sep 5. pii: 10.1007/s10549-018-4952.
    PubMed     Text format     Abstract available


  560. ALTUNDAG K
    Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients.
    Breast Cancer Res Treat. 2018 Sep 3. pii: 10.1007/s10549-018-4949.
    PubMed     Text format    


  561. OZAWA PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, et al
    Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
    Breast Cancer Res Treat. 2018 Sep 1. pii: 10.1007/s10549-018-4925.
    PubMed     Text format     Abstract available


    August 2018
  562. NAROD SA, Giannakeas V, Sopik V
    Time to death in breast cancer patients as an indicator of treatment response.
    Breast Cancer Res Treat. 2018 Aug 30. pii: 10.1007/s10549-018-4935.
    PubMed     Text format     Abstract available


  563. SHEN S, Unger JM, Crew KD, Till C, et al
    Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4946.
    PubMed     Text format     Abstract available


  564. MOORE AH, Trentham-Dietz A, Burns M, Gangnon RE, et al
    Obesity and mortality after locoregional breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4932.
    PubMed     Text format     Abstract available


  565. ZHANG Z, Li C, Fan H, Xiang Q, et al
    Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4942.
    PubMed     Text format     Abstract available


  566. DE SOUZA TIMOTEO AR, Goncalves AEMM, Sales LAP, Albuquerque BM, et al
    A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4938.
    PubMed     Text format     Abstract available


  567. THOMAS R, Rowell R, Crichton S, Cain H, et al
    Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4943.
    PubMed     Text format     Abstract available


  568. FRONTERA ED, Khansa RM, Schalk DL, Leakan LE, et al
    IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2018 Aug 28. pii: 10.1007/s10549-018-4941.
    PubMed     Text format     Abstract available


  569. GOTO-YAMAGUCHI L, Yamamoto-Ibusuki M, Yamamoto Y, Fujiki Y, et al
    Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4933.
    PubMed     Text format     Abstract available


  570. YANG J, Lv Q
    Theoretical possibility of primary breast cancer originates from ectopic breast tissue in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4926.
    PubMed     Text format    


  571. ALTUNDAG K
    Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2018 Aug 24. pii: 10.1007/s10549-018-4934.
    PubMed     Text format    


  572. BALLINGER TJ, Reddy A, Althouse SK, Nelson EM, et al
    Impact of primary breast cancer therapy on energetic capacity and body composition.
    Breast Cancer Res Treat. 2018 Aug 22. pii: 10.1007/s10549-018-4924.
    PubMed     Text format     Abstract available


  573. WANG B, Yuan F
    The association between estrogen receptor alpha gene rs746432 polymorphism and the risk of breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4929.
    PubMed     Text format    


  574. BAE SY, Nam SJ, Jung Y, Lee SB, et al
    Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4928.
    PubMed     Text format     Abstract available


  575. BEMANIAN V, Noone JC, Sauer T, Touma J, et al
    Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4927.
    PubMed     Text format     Abstract available


  576. SONG EJ, Lee CW, Jung SY, Kim BN, et al
    Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4915.
    PubMed     Text format     Abstract available


  577. RAMOS J, Das J, Felty Q, Yoo C, et al
    NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Breast Cancer Res Treat. 2018 Aug 20. pii: 10.1007/s10549-018-4905.
    PubMed     Text format     Abstract available


  578. CLAESSENS AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, et al
    Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
    Breast Cancer Res Treat. 2018 Aug 18. pii: 10.1007/s10549-018-4906.
    PubMed     Text format     Abstract available


  579. KENN M, Cacsire Castillo-Tong D, Singer CF, Cibena M, et al
    Co-expressed genes enhance precision of receptor status identification in breast cancer patients.
    Breast Cancer Res Treat. 2018 Aug 16. pii: 10.1007/s10549-018-4920.
    PubMed     Text format     Abstract available


  580. KRABY MR, Valla M, Opdahl S, Haugen OA, et al
    The prognostic value of androgen receptors in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Aug 14. pii: 10.1007/s10549-018-4904.
    PubMed     Text format     Abstract available


  581. BUHL ASK, Christensen TD, Christensen IJ, Nelausen KM, et al
    Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4918.
    PubMed     Text format     Abstract available


  582. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4919.
    PubMed     Text format     Abstract available


  583. BARBOSA C ROCHA F, Falcone AB, Buzaid AC, Pimenta JM, et al
    Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4912.
    PubMed     Text format     Abstract available


  584. GREEN AK, Aviki EM, Matsoukas K, Patil S, et al
    Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4909.
    PubMed     Text format     Abstract available


  585. BORRIE AE, Rose RV, Choi YH, Perera FE, et al
    Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4910.
    PubMed     Text format     Abstract available


  586. LEE SB, Ko SS, Park CH, Nam SJ, et al
    Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4892.
    PubMed     Text format     Abstract available


  587. CHEN BT, Jin T, Patel SK, Ye N, et al
    Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4911.
    PubMed     Text format     Abstract available


  588. BAE SY, Kim SJ, Lee J, Lee ES, et al
    Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4908.
    PubMed     Text format     Abstract available


  589. MURPHY J, Pfeiffer RM, Lynn BCD, Caballero AI, et al
    Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology.
    Breast Cancer Res Treat. 2018 Aug 6. pii: 10.1007/s10549-018-4907.
    PubMed     Text format     Abstract available


  590. ZDRAVKOVIC D, Nikolic D, Zdravkovic M
    Heterogeneity of tumor cells and metastases in breast cancer patients: cause or consequence?
    Breast Cancer Res Treat. 2018 Aug 4. pii: 10.1007/s10549-018-4913.
    PubMed     Text format    


  591. LIN CH, Tang CH
    Rebuttal comments on "Glucocorticoids in breast cancer treatment: Real benefit or selection bias?"
    Breast Cancer Res Treat. 2018 Aug 2. pii: 10.1007/s10549-018-4872.
    PubMed     Text format    


    July 2018
  592. SANFT T, Usiskin I, Harrigan M, Cartmel B, et al
    Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4895.
    PubMed     Text format     Abstract available


  593. SUN F, Hall A, Tighe MP, Brunelle CL, et al
    Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4902.
    PubMed     Text format     Abstract available


  594. FELIZ-MOSQUEA YR, Christensen AA, Wilson AS, Westwood B, et al
    Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4884.
    PubMed     Text format     Abstract available


  595. KUROZUMI S, Joseph C, Sonbul S, Aleskandarany MA, et al
    Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4891.
    PubMed     Text format     Abstract available


  596. MESSINA C, Cattrini C, Buzzatti G, Cerbone L, et al
    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4901.
    PubMed     Text format     Abstract available


  597. LIN JH, Tu SH, Chen LC, Huang CC, et al
    Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4897.
    PubMed     Text format     Abstract available


  598. GUNER G, Dizdar O
    Glucocorticoids in breast cancer treatment: real benefit or selection bias?
    Breast Cancer Res Treat. 2018 Jul 26. pii: 10.1007/s10549-018-4871.
    PubMed     Text format    


  599. FARSHID G, Walters D
    Molecular subtypes of screen-detected breast cancer.
    Breast Cancer Res Treat. 2018 Jul 25. pii: 10.1007/s10549-018-4899.
    PubMed     Text format     Abstract available


  600. MADDEN JM, Murphy L, Zgaga L, Bennett K, et al
    De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4896.
    PubMed     Text format     Abstract available


  601. SHARIF-ASKARI B, Amrein L, Aloyz R, Panasci L, et al
    PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4888.
    PubMed     Text format     Abstract available


  602. WULANINGSIH W, Garmo H, Ahlgren J, Holmberg L, et al
    Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
    Breast Cancer Res Treat. 2018 Jul 21. pii: 10.1007/s10549-018-4890.
    PubMed     Text format     Abstract available


  603. TERADA M, Adachi Y, Sawaki M, Hattori M, et al
    Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Jul 20. pii: 10.1007/s10549-018-4898.
    PubMed     Text format     Abstract available


  604. SOLDERA SV, Ennis M, Lohmann AE, Goodwin PJ, et al
    Sexual health in long-term breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jul 19. pii: 10.1007/s10549-018-4894.
    PubMed     Text format     Abstract available


  605. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4893.
    PubMed     Text format     Abstract available


  606. MCCALL NS, Simone BA, Mehta M, Zhan T, et al
    Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4880.
    PubMed     Text format     Abstract available


  607. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jul 16. pii: 10.1007/s10549-018-4883.
    PubMed     Text format     Abstract available


  608. VAN NULAND M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, et al
    Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4886.
    PubMed     Text format     Abstract available


  609. O'BRIEN KM, Mooney T, Fitzpatrick P, Sharp L, et al
    Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4877.
    PubMed     Text format     Abstract available


  610. REDITI M, Messina C
    Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4885.
    PubMed     Text format    


  611. BANYS-PALUCHOWSKI M, Witzel I, Riethdorf S, Pantel K, et al
    The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4882.
    PubMed     Text format     Abstract available


  612. SAHA A, Harowicz MR, Cain EH, Hall AH, et al
    Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
    Breast Cancer Res Treat. 2018 Jul 10. pii: 10.1007/s10549-018-4879.
    PubMed     Text format     Abstract available


  613. NIKOLIC D, Granic M, Ivanovic N, Zdravkovic D, et al
    Breast cancer and its impact in male transsexuals.
    Breast Cancer Res Treat. 2018 Jul 5. pii: 10.1007/s10549-018-4875.
    PubMed     Text format     Abstract available


  614. ANGARITA FA, Elmi M, Zhang Y, Look Hong NJ, et al
    Patient-reported factors influencing the treatment decision-making process of older women with non-metastatic breast cancer: a systematic review of qualitative evidence.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4865.
    PubMed     Text format     Abstract available


  615. ROBINSON A, Souied O, Bota AB, Levasseur N, et al
    Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4868.
    PubMed     Text format     Abstract available


  616. WANG J, Xu B, Wang W, Zhai X, et al
    Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4867.
    PubMed     Text format     Abstract available


  617. KABIL N, Bayraktar R, Kahraman N, Mokhlis HA, et al
    Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4847.
    PubMed     Text format     Abstract available


  618. BERTHE A, Zaffino M, Muller C, Foulquier F, et al
    Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4874.
    PubMed     Text format     Abstract available


  619. SAGARA Y, Takada M, Ohi Y, Ohtani S, et al
    Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4873.
    PubMed     Text format     Abstract available


    June 2018
  620. BRENNAN M, Gass P, Haberle L, Wang D, et al
    The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer.
    Breast Cancer Res Treat. 2018 Jun 27. pii: 10.1007/s10549-018-4829.
    PubMed     Text format     Abstract available


  621. STOUT NK, Cronin AM, Uno H, Ozanne EM, et al
    Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
    Breast Cancer Res Treat. 2018 Jun 26. pii: 10.1007/s10549-018-4860.
    PubMed     Text format     Abstract available


  622. LEE DY, Park YH, Lee JE, Choi D, et al
    Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4863.
    PubMed     Text format     Abstract available


  623. VAN SWEARINGEN AED, Siegel MB, Deal AM, Sambade MJ, et al
    LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4852.
    PubMed     Text format     Abstract available


  624. YAP YS, Munusamy P, Lim C, Chan CHT, et al
    Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4851.
    PubMed     Text format     Abstract available


  625. KIM JY, Lim JE, Jung HH, Cho SY, et al
    Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4858.
    PubMed     Text format     Abstract available


  626. BAUER ECA, Schochter F, Widschwendter P, DeGregorio A, et al
    Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4856.
    PubMed     Text format     Abstract available


  627. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jun 19. pii: 10.1007/s10549-018-4855.
    PubMed     Text format     Abstract available


  628. PEREIRA PTVT, Reis AD, Diniz RR, Lima FA, et al
    Dietary supplements and fatigue in patients with breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4857.
    PubMed     Text format     Abstract available


  629. JERZAK KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, et al
    Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4844.
    PubMed     Text format     Abstract available


  630. KOGAWA T, Fujii T, Fouad TM, Liu DD, et al
    Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4853.
    PubMed     Text format     Abstract available


  631. LI X, Zhang Y, Meisel J, Jiang R, et al
    Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
    Breast Cancer Res Treat. 2018 Jun 15. pii: 10.1007/s10549-018-4832.
    PubMed     Text format     Abstract available


  632. LANGBALLE R, Frederiksen K, Jensen MB, Andersson M, et al
    Mortality after contralateral breast cancer in Denmark.
    Breast Cancer Res Treat. 2018 Jun 11. pii: 10.1007/s10549-018-4846.
    PubMed     Text format     Abstract available


  633. MANDUJANO-TINOCO EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V, et al
    New emerging roles of microRNAs in breast cancer.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4850.
    PubMed     Text format     Abstract available


  634. SMITH BL, Gadd MA, Lanahan CR, Rai U, et al
    Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4845.
    PubMed     Text format     Abstract available


  635. LOTSCH J, Sipila R, Tasmuth T, Kringel D, et al
    Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy.
    Breast Cancer Res Treat. 2018 Jun 6. pii: 10.1007/s10549-018-4841.
    PubMed     Text format     Abstract available


  636. KONG AL, Nattinger AB, McGinley E, Pezzin LE, et al
    The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4837.
    PubMed     Text format     Abstract available


  637. ROUMELIOTIS M, Long K, Phan T, Graham D, et al
    Including internal mammary lymph nodes in radiation therapy for synchronous bilateral breast cancer: an international survey of treatment technique and clinical priorities.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4848.
    PubMed     Text format     Abstract available


  638. CHA YJ, Ahn SG, Bae SJ, Yoon CI, et al
    Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4842.
    PubMed     Text format     Abstract available


  639. PICADO O, Khazeni K, Allen C, Yakoub D, et al
    Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4840.
    PubMed     Text format     Abstract available


  640. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4819.
    PubMed     Text format     Abstract available


  641. REDDY JP, Atkinson RL, Larson R, Burks JK, et al
    Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4835.
    PubMed     Text format     Abstract available


  642. ARIAS-PULIDO H, Cimino-Mathews A, Chaher N, Qualls C, et al
    The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4834.
    PubMed     Text format     Abstract available


  643. EVANS A, Sim YT, Pourreyron C, Thompson A, et al
    Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4836.
    PubMed     Text format     Abstract available


    May 2018
  644. JAIN S, Shah AN, Santa-Maria CA, Siziopikou K, et al
    Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4792.
    PubMed     Text format     Abstract available


  645. ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
    Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4820.
    PubMed     Text format     Abstract available


  646. JACOB L, Scholten PC, Kostev K, Kalder M, et al
    Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4831.
    PubMed     Text format     Abstract available


  647. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4839.
    PubMed     Text format     Abstract available


  648. LIU J, Yang Y, Wang H, Wang B, et al
    Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4833.
    PubMed     Text format     Abstract available


  649. ELMI M, Sequeira S, Azin A, Elnahas A, et al
    Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2018 May 28. pii: 10.1007/s10549-018-4830.
    PubMed     Text format     Abstract available


  650. LI D, McCall LM, Hahn OM, Hudis CA, et al
    Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
    Breast Cancer Res Treat. 2018 May 22. pii: 10.1007/s10549-018-4828.
    PubMed     Text format     Abstract available


  651. MASUMOTO N, Kadoya T, Sasada S, Emi A, et al
    Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
    Breast Cancer Res Treat. 2018 May 19. pii: 10.1007/s10549-018-4791.
    PubMed     Text format     Abstract available


  652. KOTSOPOULOS J, Gronwald J, Lynch HT, Eisen A, et al
    Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4822.
    PubMed     Text format     Abstract available


  653. O'LOUGHLIN M, Andreu X, Bianchi S, Chemielik E, et al
    Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4825.
    PubMed     Text format     Abstract available


  654. WILLIAMSON TJ, Love SM, Clague DeHart JN, Jorge-Miller A, et al
    Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4823.
    PubMed     Text format     Abstract available


  655. HOSTE G, Punie K, Wildiers H, Beuselinck B, et al
    Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4827.
    PubMed     Text format     Abstract available


  656. BLOK EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, et al
    Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2018 May 15. pii: 10.1007/s10549-018-4785.
    PubMed     Text format     Abstract available


  657. LIN CH, Chuang PY, You SL, Chiang CJ, et al
    Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
    Breast Cancer Res Treat. 2018 May 14. pii: 10.1007/s10549-018-4787.
    PubMed     Text format     Abstract available


  658. LU CY, Zhang F, Wagner AK, Nekhlyudov L, et al
    Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
    Breast Cancer Res Treat. 2018 May 12. pii: 10.1007/s10549-018-4821.
    PubMed     Text format     Abstract available


  659. ONO H, Sowa Y, Horinaka M, Iizumi Y, et al
    The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Breast Cancer Res Treat. 2018 May 11. pii: 10.1007/s10549-018-4815.
    PubMed     Text format     Abstract available


  660. LOWRY KP, Braunstein LZ, Economopoulos KP, Salama L, et al
    Predictors of surveillance mammography outcomes in women with a personal history of breast cancer.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4808.
    PubMed     Text format     Abstract available


  661. WANG S, Beeghly-Fadiel A, Cai Q, Cai H, et al
    Gene expression in triple-negative breast cancer in relation to survival.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4816.
    PubMed     Text format     Abstract available


  662. HUANG Z, Shi Y, Bao P, Cai H, et al
    Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4805.
    PubMed     Text format     Abstract available


  663. BARDIA A, Gucalp A, DaCosta N, Gabrail N, et al
    Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4813.
    PubMed     Text format     Abstract available


  664. CHOI JY, Cho EY, Choi YJ, Lee JH, et al
    Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4809.
    PubMed     Text format     Abstract available


  665. CUI P, Zhao Y, Chu X, He N, et al
    SNP rs2071095 in LincRNA H19 is associated with breast cancer risk.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4814.
    PubMed     Text format     Abstract available


  666. DANIELS B, Kiely BE, Lord SJ, Houssami N, et al
    Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4804.
    PubMed     Text format     Abstract available


  667. TELLI ML, Stover DG, Loi S, Aparicio S, et al
    Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4807.
    PubMed     Text format     Abstract available


  668. TSUNASHIMA R, Naoi Y, Shimazu K, Kagara N, et al
    Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4812.
    PubMed     Text format     Abstract available


  669. ABRAHAM J, Coleman R, Elias A, Holmes FA, et al
    Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4783.
    PubMed     Text format     Abstract available


  670. WUNDERLE M, Gass P, Haberle L, Flesch VM, et al
    BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    Breast Cancer Res Treat. 2018 May 3. pii: 10.1007/s10549-018-4797.
    PubMed     Text format     Abstract available


  671. KOMMALAPATI A, Tella SH, Goyal G, Ganti AK, et al
    A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4802.
    PubMed     Text format     Abstract available


  672. ERIN N, Ogan N, Yerlikaya A
    Correction to: Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4781.
    PubMed     Text format     Abstract available


    April 2018
  673. KIM S, Ko Y, Lee HJ, Lim JE, et al
    Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.
    Breast Cancer Res Treat. 2018 Apr 30. pii: 10.1007/s10549-018-4782.
    PubMed     Text format     Abstract available


  674. SHIMA H, Kida K, Adachi S, Yamada A, et al
    Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4793.
    PubMed     Text format     Abstract available


  675. VOCI A, Lee D, Ho E, Crane-Okada R, et al
    Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4790.
    PubMed     Text format     Abstract available


  676. BACHAND J, Soulos PR, Herrin J, Pollack CE, et al
    Physician peer group characteristics and timeliness of breast cancer surgery.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4789.
    PubMed     Text format     Abstract available


  677. HAQUE W, Verma V, Hatch S, Suzanne Klimberg V, et al
    Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4801.
    PubMed     Text format     Abstract available


  678. SOPIK V, Narod SA
    The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4796.
    PubMed     Text format     Abstract available


  679. HACKETT J, Thorneloe R, Side L, Wolf M, et al
    Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4775.
    PubMed     Text format     Abstract available


  680. O'SHAUGHNESSY J, DeMichele A, Ma CX, Richards P, et al
    A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    Breast Cancer Res Treat. 2018 Apr 19. pii: 10.1007/s10549-018-4770.
    PubMed     Text format     Abstract available


  681. KROENKE CH, Hershman DL, Gomez SL, Adams SR, et al
    Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Breast Cancer Res Treat. 2018 Apr 18. pii: 10.1007/s10549-018-4774.
    PubMed     Text format     Abstract available


  682. SOARES FALCETTA F, de Araujo Vianna Trasel H, de Almeida FK, Rangel Ribeiro Falcetta M, et al
    Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4786.
    PubMed     Text format     Abstract available


  683. VERMA S, O'Shaughnessy J, Burris HA, Campone M, et al
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4769.
    PubMed     Text format     Abstract available


  684. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort.
    Breast Cancer Res Treat. 2018 Apr 12. pii: 10.1007/s10549-018-4784.
    PubMed     Text format     Abstract available


  685. ARTHUR R, Wang Y, Ye K, Glass AG, et al
    Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat. 2018 Apr 11. pii: 10.1007/s10549-018-4780.
    PubMed     Text format     Abstract available


  686. LARSEN SB, Torstensson M, Kenborg L, Christensen J, et al
    Pre-diagnostic changes in body mass index and mortality among breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 10. pii: 10.1007/s10549-018-4771.
    PubMed     Text format     Abstract available


  687. KUROZUMI S, Joseph C, Sonbul S, Gorringe KL, et al
    Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
    Breast Cancer Res Treat. 2018 Apr 9. pii: 10.1007/s10549-018-4777.
    PubMed     Text format     Abstract available


  688. PETROSSIAN K, Nguyen D, Lo C, Kanaya N, et al
    Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4779.
    PubMed     Text format     Abstract available


  689. CHECK DK, Chawla N, Kwan ML, Pinheiro L, et al
    Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4776.
    PubMed     Text format     Abstract available


  690. RAU KM, Ou-Yang F, Chao TC, Kuo YL, et al
    Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4778.
    PubMed     Text format     Abstract available


  691. GHILLI M, Mariniello MD, Scatena C, Dosa L, et al
    Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature.
    Breast Cancer Res Treat. 2018 Apr 3. pii: 10.1007/s10549-018-4772.
    PubMed     Text format     Abstract available


  692. SCHWARTZ MD, Peshkin BN, Isaacs C, Willey S, et al
    Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 2. pii: 10.1007/s10549-018-4773.
    PubMed     Text format     Abstract available


    March 2018
  693. MUNZONE E, Gray KP, Fumagalli C, Guerini-Rocco E, et al
    Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Breast Cancer Res Treat. 2018 Mar 27. pii: 10.1007/s10549-018-4767.
    PubMed     Text format     Abstract available


  694. CHOWDHURY M, Euhus D, Arun B, Umbricht C, et al
    Validation of a personalized risk prediction model for contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4763.
    PubMed     Text format     Abstract available


  695. BHAT RR, Yadav P, Sahay D, Bhargava DK, et al
    GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4751.
    PubMed     Text format     Abstract available


  696. CAI H, Guo W, Zhang S, Li N, et al
    A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4758.
    PubMed     Text format     Abstract available


  697. PHILLIPS M, Cataneo RN, Cruz-Ramos JA, Huston J, et al
    Prediction of breast cancer risk with volatile biomarkers in breath.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4764.
    PubMed     Text format     Abstract available


  698. RISI E, Grilli A, Migliaccio I, Biagioni C, et al
    A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4766.
    PubMed     Text format     Abstract available


  699. AGERSBORG S, Mixon C, Nguyen T, Aithal S, et al
    Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4755.
    PubMed     Text format     Abstract available


  700. HILL DA, Friend S, Lomo L, Wiggins C, et al
    Breast cancer survival, survival disparities, and guideline-based treatment.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4761.
    PubMed     Text format     Abstract available


  701. DUFFY MJ, Synnott NC, Crown J
    Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4753.
    PubMed     Text format     Abstract available


  702. CHATTERJEE S, Chaubal R, Maitra A, Gardi N, et al
    Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4749.
    PubMed     Text format     Abstract available


  703. BOYD J
    A parallel model for breast cancer metastasis.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4759.
    PubMed     Text format    


  704. SCHAYEK H, Korach H, Laitman Y, Bernstein-Molho R, et al
    Mutational analysis of candidate genes in Israeli male breast cancer cases.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4765.
    PubMed     Text format     Abstract available


  705. LI M, Zhou Y, Xia T, Zhou X, et al
    Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4757.
    PubMed     Text format     Abstract available


  706. ALTUNDAG K
    Receptor conversion in breast cancer patients with liver metastases after hepatectomy might affect survival.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4762.
    PubMed     Text format    


  707. ERIN N, Ogan N, Yerlikaya A
    Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4752.
    PubMed     Text format     Abstract available


  708. THONE K, Rudolph A, Obi N, Chang-Claude J, et al
    Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis.
    Breast Cancer Res Treat. 2018 Mar 19. pii: 10.1007/s10549-018-4754.
    PubMed     Text format     Abstract available


  709. KYKER-SNOWMAN K, Erlanger Avigdor B, Nasim M, Cimino-Mathews A, et al
    A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4742.
    PubMed     Text format     Abstract available


  710. ANGARITA FA, Acuna SA, Cordeiro E, Elnahas A, et al
    Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4747.
    PubMed     Text format     Abstract available


  711. BOUYA S, Koochakzai M, Rafiemanesh H, Balouchi A, et al
    Health-related quality of life of Iranian breast cancer patients: a meta-analysis and systematic review.
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4750.
    PubMed     Text format     Abstract available


  712. NAROD SA
    Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4739.
    PubMed     Text format    


  713. WILSON LE, Pollack CE, Greiner MA, Dinan MA, et al
    Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Breast Cancer Res Treat. 2018 Mar 13. pii: 10.1007/s10549-018-4746.
    PubMed     Text format     Abstract available


  714. TURNER TH, Alzubi MA, Sohal SS, Olex AL, et al
    Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Mar 12. pii: 10.1007/s10549-018-4748.
    PubMed     Text format     Abstract available


  715. ROY P, Leizorovicz A, Villet R, Mercier C, et al
    Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial.
    Breast Cancer Res Treat. 2018 Mar 10. pii: 10.1007/s10549-018-4733.
    PubMed     Text format     Abstract available


  716. LI Y, Opyrchal M, Yao S, Peng X, et al
    The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Breast Cancer Res Treat. 2018 Mar 9. pii: 10.1007/s10549-018-4745.
    PubMed     Text format     Abstract available


  717. BAO T, Iris Zhi W, Vertosick EA, Li QS, et al
    Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4743.
    PubMed     Text format     Abstract available


  718. BLANCHETTE PS, Desautels DN, Pond GR, Bartlett JMS, et al
    Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4734.
    PubMed     Text format     Abstract available


  719. PARK SJ, Lee MH, Kong SY, Song MK, et al
    Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4740.
    PubMed     Text format     Abstract available


  720. VELASQUEZ GARCIA HA, Sobolev BG, Gotay CC, Wilson CM, et al
    Mammographic non-dense area and breast cancer risk in postmenopausal women: a causal inference approach in a case-control study.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4737.
    PubMed     Text format     Abstract available


  721. ONEGA T, Zhu W, Weiss JE, Goodrich M, et al
    Preoperative breast MRI and mortality in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4732.
    PubMed     Text format     Abstract available


  722. ADAMS BD, Arem H, Hubal MJ, Cartmel B, et al
    Exercise and weight loss interventions and miRNA expression in women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4738.
    PubMed     Text format     Abstract available


  723. CHOWDHURY M, Euhus D, O'Donnell M, Onega T, et al
    Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4736.
    PubMed     Text format     Abstract available


  724. RICE MS, Tamimi RM, Bertrand KA, Scott CG, et al
    Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.
    Breast Cancer Res Treat. 2018 Mar 3. pii: 10.1007/s10549-018-4735.
    PubMed     Text format     Abstract available


    February 2018
  725. GERNAAT SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, et al
    The risk of cardiovascular disease following breast cancer by Framingham risk score.
    Breast Cancer Res Treat. 2018 Feb 28. pii: 10.1007/s10549-018-4723.
    PubMed     Text format     Abstract available


  726. KUSHNER CJ, Hwang WT, Wang S, Solin LJ, et al
    Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer.
    Breast Cancer Res Treat. 2018 Feb 27. pii: 10.1007/s10549-018-4729.
    PubMed     Text format     Abstract available


  727. CHEN R, Ye Y, Yang C, Peng Y, et al
    Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4730.
    PubMed     Text format     Abstract available


  728. BRONTE G, Ravaioli S, Bravaccini S
    What to look for in cell-free DNA from breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4728.
    PubMed     Text format    


  729. CHENG J, Burwinkel B
    Cell-free DNA in breast cancer: a long way to go.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4731.
    PubMed     Text format    


  730. EBER-SCHULZ P, Tariku W, Reibold C, Addissie A, et al
    Survival of breast cancer patients in rural Ethiopia.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4724.
    PubMed     Text format     Abstract available


  731. DE VRIES YC, Boesveldt S, Kelfkens CS, Posthuma EE, et al
    Taste and smell perception and quality of life during and after systemic therapy for breast cancer.
    Breast Cancer Res Treat. 2018 Feb 23. pii: 10.1007/s10549-018-4720.
    PubMed     Text format     Abstract available


  732. CLIFTON K, Gutierrez-Barrera A, Ma J, Bassett R Jr., et al
    Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4727.
    PubMed     Text format     Abstract available


  733. BAUMANN FT, Reike A, Reimer V, Schumann M, et al
    Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4725.
    PubMed     Text format     Abstract available


  734. CHA YJ, Kim ES, Koo JS
    Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4722.
    PubMed     Text format     Abstract available


  735. JOHNSON J, Bessette DC, Saunus JM, Smart CE, et al
    Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4719.
    PubMed     Text format     Abstract available


  736. RUIZ A, Sebagh M, Wicherts DA, Castro-Benitez C, et al
    Long-term survival and cure model following liver resection for breast cancer metastases.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4714.
    PubMed     Text format     Abstract available


  737. RUDOLPH M, Sizemore ST, Lu Y, Teng KY, et al
    A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4718.
    PubMed     Text format     Abstract available


  738. WEISS A, Menen RS, Lin HY, Shen Y, et al
    Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4715.
    PubMed     Text format     Abstract available


  739. TOT T
    Metastasis of breast cancer prior to invasion.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4721.
    PubMed     Text format    


  740. JACOBS DHM, Speijer G, Petoukhova AL, Roeloffzen EMA, et al
    Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4712.
    PubMed     Text format     Abstract available


  741. TOLKACH Y, Gevensleben H, Bundschuh R, Koyun A, et al
    Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4717.
    PubMed     Text format     Abstract available


  742. WAGNER LI, Zhao F, Goss PE, Chapman JW, et al
    Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4713.
    PubMed     Text format     Abstract available


  743. SCHAIRER C, Freedman DM, Gadalla SM, Pfeiffer RM, et al
    Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.
    Breast Cancer Res Treat. 2018 Feb 15. pii: 10.1007/s10549-018-4680.
    PubMed     Text format     Abstract available


  744. SHOEMAKER ML, White MC, Wu M, Weir HK, et al
    Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4699.
    PubMed     Text format     Abstract available


  745. GIANNAKEAS V, Sopik V, Narod SA
    A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4716.
    PubMed     Text format     Abstract available


  746. DEHDASHTI F, Wu N, Bose R, Naughton MJ, et al
    Evaluation of [(89)Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4696.
    PubMed     Text format     Abstract available


  747. COLLARINO A, Valdes Olmos RA, van Berkel LGAJ, Neijenhuis PA, et al
    The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4706.
    PubMed     Text format     Abstract available


  748. CHANG JH, Shin KH, Ahn SD, Park HJ, et al
    Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4707.
    PubMed     Text format     Abstract available


  749. HOLLINGSWORTH AB
    Is invasion a necessary step for metastases in breast cancer? Narod SA, Sopik V.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4702.
    PubMed     Text format    


  750. XIE B, Yuan Z, Yang Y, Sun Z, et al
    MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4708.
    PubMed     Text format     Abstract available


  751. SKAANE P, Sebuodegard S, Bandos AI, Gur D, et al
    Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4705.
    PubMed     Text format     Abstract available


  752. DE MULDER H, Laenen A, Wildiers H, Punie K, et al
    Breast cancer subtype and survival by parity and time since last birth.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4701.
    PubMed     Text format     Abstract available


  753. MIYAKE KK, Nakamoto Y, Saji S, Sugie T, et al
    Impact of physiological hormonal fluctuations on (18)F-fluorodeoxyglucose uptake in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4711.
    PubMed     Text format     Abstract available


  754. GOLDVASER H, Majeed H, Ribnikar D, Seruga B, et al
    Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4710.
    PubMed     Text format     Abstract available


  755. COSTA RLB, Han HS, Gradishar WJ
    Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Breast Cancer Res Treat. 2018 Feb 7. pii: 10.1007/s10549-018-4697.
    PubMed     Text format     Abstract available


  756. ZAREI N, Fazeli M, Mohammadi M, Nejatollahi F, et al
    Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.
    Breast Cancer Res Treat. 2018 Feb 6. pii: 10.1007/s10549-017-4641.
    PubMed     Text format     Abstract available


  757. LAMMERT J, Lubinski J, Gronwald J, Huzarski T, et al
    Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-018-4694.
    PubMed     Text format     Abstract available


  758. JANNI W, Alba E, Bachelot T, Diab S, et al
    First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-017-4658.
    PubMed     Text format     Abstract available


  759. VALDORA F, Houssami N, Rossi F, Calabrese M, et al
    Rapid review: radiomics and breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-018-4675.
    PubMed     Text format     Abstract available


  760. FOLDI J, Mougalian S, Silber A, Lannin D, et al
    Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-017-4653.
    PubMed     Text format     Abstract available


  761. ZHOU S, Wang L, Yang Q, Liu H, et al
    Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4678.
    PubMed     Text format     Abstract available


  762. MATOSSIAN MD, Burks HE, Bowles AC, Elliott S, et al
    A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4685.
    PubMed     Text format     Abstract available


    January 2018
  763. LEE SB, Sohn G, Kim J, Chung IY, et al
    A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
    Breast Cancer Res Treat. 2018 Jan 31. pii: 10.1007/s10549-018-4682.
    PubMed     Text format     Abstract available


  764. HWANG KT, Kim EK, Jung SH, Lee ES, et al
    Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Breast Cancer Res Treat. 2018 Jan 30. pii: 10.1007/s10549-018-4681.
    PubMed     Text format     Abstract available


  765. JANSSON S, Aaltonen K, Bendahl PO, Falck AK, et al
    The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
    Breast Cancer Res Treat. 2018 Jan 29. pii: 10.1007/s10549-018-4664.
    PubMed     Text format     Abstract available


  766. FAIRWEATHER M, Jiang W, Keating NL, Freedman RA, et al
    Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry.
    Breast Cancer Res Treat. 2018 Jan 27. pii: 10.1007/s10549-018-4689.
    PubMed     Text format     Abstract available


  767. ZHANG L, Yu Q, Wu XC, Hsieh MC, et al
    Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-017-4646.
    PubMed     Text format     Abstract available


  768. GOYAL NG, Levine BJ, Van Zee KJ, Naftalis E, et al
    Trajectories of quality of life following breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-018-4677.
    PubMed     Text format     Abstract available


  769. POURCELOT C, Orillard E, Nallet G, Dirand C, et al
    Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence.
    Breast Cancer Res Treat. 2018 Jan 23. pii: 10.1007/s10549-018-4676.
    PubMed     Text format     Abstract available


  770. FAN Z, Ouyang T, Li J, Wang T, et al
    Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Jan 22. pii: 10.1007/s10549-018-4673.
    PubMed     Text format     Abstract available


  771. JONES T, Duquette D, Underhill M, Ming C, et al
    Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry.
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-018-4674.
    PubMed     Text format     Abstract available


  772. NAROD SA, Sopik V
    Is invasion a necessary step for metastases in breast cancer?
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-017-4644.
    PubMed     Text format     Abstract available


  773. BAO T, Seidman A, Li Q, Seluzicki C, et al
    Living with chronic pain: perceptions of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4670.
    PubMed     Text format     Abstract available


  774. ABRAHAM J, Caldera H, Coleman R, Elias A, et al
    Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4662.
    PubMed     Text format     Abstract available


  775. MIJWEL S, Backman M, Bolam KA, Olofsson E, et al
    Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4663.
    PubMed     Text format     Abstract available


  776. PEDERSON HJ, Hussain N, Noss R, Yanda C, et al
    Impact of an embedded genetic counselor on breast cancer treatment.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-017-4643.
    PubMed     Text format     Abstract available


  777. KOOPMAN T, Buikema HJ, Hollema H, de Bock GH, et al
    Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4669.
    PubMed     Text format     Abstract available


  778. BREYER JZ, Wendland EM, Kops NL, Caleffi M, et al
    Assessment of potential risk factors for breast cancer in a population in Southern Brazil.
    Breast Cancer Res Treat. 2018 Jan 17. pii: 10.1007/s10549-017-4655.
    PubMed     Text format     Abstract available


  779. GARCIA GARRE E, Luengo Gil G, Montoro Garcia S, Gonzalez Billalabeitia E, et al
    Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4656.
    PubMed     Text format     Abstract available


  780. CHENG J, Holland-Letz T, Wallwiener M, Surowy H, et al
    Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-018-4666.
    PubMed     Text format     Abstract available


  781. NI YB, Tsang JYS, Shao MM, Chan SK, et al
    GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4645.
    PubMed     Text format     Abstract available


  782. FOSTIRA F, Saloustros E, Apostolou P, Vagena A, et al
    Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-018-4661.
    PubMed     Text format     Abstract available


  783. JAKIMOVSKA M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, et al
    BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4642.
    PubMed     Text format     Abstract available


  784. LAMBERTINI M, Fontanella C
    How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4654.
    PubMed     Text format    


  785. POORVU PD, Vaz-Luis I, Freedman RA, Lin NU, et al
    Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4659.
    PubMed     Text format     Abstract available


  786. ZHANG Y, Ji Y, Li J, Lei L, et al
    Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4660.
    PubMed     Text format     Abstract available


  787. PAN K, Hurria A, Chlebowski RT
    Breast cancer survivorship: state of the science.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-017-4650.
    PubMed     Text format     Abstract available


  788. PAN Y, Heisig SR, von Blanckenburg P, Albert US, et al
    Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4637.
    PubMed     Text format     Abstract available


  789. NUNCIA-CANTARERO M, Martinez-Canales S, Andres-Pretel F, Santpere G, et al
    Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4652.
    PubMed     Text format     Abstract available


  790. TAN Q, Wei C
    Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4648.
    PubMed     Text format    


  791. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 11. pii: 10.1007/s10549-017-4634.
    PubMed     Text format     Abstract available



  792. 1st UK Interdisciplinary Breast Cancer Symposium-15th-16th January 2018.
    Breast Cancer Res Treat. 2018 Jan 10. pii: 10.1007/s10549-017-4585.
    PubMed     Text format    


  793. LILJEGREN A, von Wachenfeldt A, Azavedo E, Eloranta S, et al
    Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Breast Cancer Res Treat. 2018 Jan 9. pii: 10.1007/s10549-017-4639.
    PubMed     Text format     Abstract available


  794. CHAE JW, Chua PS, Ng T, Yeo AHL, et al
    Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
    Breast Cancer Res Treat. 2018 Jan 8. pii: 10.1007/s10549-017-4640.
    PubMed     Text format     Abstract available


  795. BRAVACCINI S, Rocca A, Bronte G
    Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 6. pii: 10.1007/s10549-017-4630.
    PubMed     Text format    


  796. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 5. pii: 10.1007/s10549-017-4633.
    PubMed     Text format     Abstract available


  797. WANG S, Qian F, Zheng Y, Ogundiran T, et al
    Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry.
    Breast Cancer Res Treat. 2018 Jan 4. pii: 10.1007/s10549-017-4638.
    PubMed     Text format     Abstract available


  798. KOSTEV K, Kalder M
    20-year risk of breast cancer recurrence.
    Breast Cancer Res Treat. 2018 Jan 3. pii: 10.1007/s10549-017-4636.
    PubMed     Text format    


    December 2017
  799. HADDAD TC, D'Assoro A, Suman V, Opyrchal M, et al
    Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 30. pii: 10.1007/s10549-017-4616.
    PubMed     Text format     Abstract available


  800. PONDE N, Bradbury I, Lambertini M, Ewer M, et al
    Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
    Breast Cancer Res Treat. 2017 Dec 27. pii: 10.1007/s10549-017-4628.
    PubMed     Text format     Abstract available


  801. KOSTEV K, Kalder M
    Long-term use of basal insulin and the risk of breast cancer.
    Breast Cancer Res Treat. 2017 Dec 26. pii: 10.1007/s10549-017-4631.
    PubMed     Text format    


  802. TELLI ML, Hellyer J, Audeh W, Jensen KC, et al
    Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Breast Cancer Res Treat. 2017 Dec 23. pii: 10.1007/s10549-017-4624.
    PubMed     Text format     Abstract available


  803. FAZZINO TL, Klemp J, Befort C
    Late breast cancer treatment-related symptoms and functioning: associations with physical activity adoption and maintenance during a lifestyle intervention for rural survivors.
    Breast Cancer Res Treat. 2017 Dec 22. pii: 10.1007/s10549-017-4603.
    PubMed     Text format     Abstract available


  804. PICHILINGUE-FEBRES AF, Arias-Linares MA, Araujo-Castillo RV
    Comments on "Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors" by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
    Breast Cancer Res Treat. 2017 Dec 21. pii: 10.1007/s10549-017-4620.
    PubMed     Text format     Abstract available


  805. UNDERWOOD EA, Rochon PA, Moineddin R, Lee PE, et al
    Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2017 Dec 20. pii: 10.1007/s10549-017-4627.
    PubMed     Text format     Abstract available


  806. DUGGAN C, Baumgartner RN, Baumgartner KB, Bernstein L, et al
    Genetic variation in TNFalpha, PPARgamma, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4621.
    PubMed     Text format     Abstract available


  807. VAN SEIJEN M, Mooyaart AL, Mulder L, Hoogstraat M, et al
    Enrichment of high-grade tumors in breast cancer gene expression studies.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4622.
    PubMed     Text format     Abstract available


  808. KWAN ML, Yao S, Laurent CA, Roh JM, et al
    Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2017 Dec 16. pii: 10.1007/s10549-017-4626.
    PubMed     Text format     Abstract available


  809. DU RUSQUEC P, Palpacuer C, Campion L, Patsouris A, et al
    Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4623.
    PubMed     Text format     Abstract available


  810. NAROD SA, Huzarski T, Gronwald J, Byrski T, et al
    Predictors of survival for breast cancer patients with a BRCA1 mutation.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4605.
    PubMed     Text format     Abstract available


  811. ZIMMER AS, Zhu K, Steeg PS, Wu A, et al
    Analysis of breast cancer in young women in the Department of Defense (DOD) database.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4615.
    PubMed     Text format     Abstract available


  812. FALANDRY C, Krakowski I, Cure H, Carola E, et al
    Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.
    Breast Cancer Res Treat. 2017 Dec 14. pii: 10.1007/s10549-017-4607.
    PubMed     Text format     Abstract available


  813. FANG H, Huang D, Yang F, Guan X, et al
    Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Dec 13. pii: 10.1007/s10549-017-4612.
    PubMed     Text format     Abstract available


  814. HAN SN, Amant F, Cardonick EH, Loibl S, et al
    Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4611.
    PubMed     Text format     Abstract available


  815. BENS A, Papadopoulos FC, Pukkala E, Ekbom A, et al
    Worse survival after breast cancer in women with anorexia nervosa.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4618.
    PubMed     Text format     Abstract available


  816. VAN VULPEN JK, Schmidt ME, Velthuis MJ, Wiskemann J, et al
    Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4608.
    PubMed     Text format     Abstract available


  817. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4601.
    PubMed     Text format     Abstract available


  818. SPEIGL L, Burow H, Bailur JK, Janssen N, et al
    CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4594.
    PubMed     Text format     Abstract available


  819. XIE J, Cao J, Wang JF, Zhang BH, et al
    Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4609.
    PubMed     Text format     Abstract available


  820. SINGH K, He X, Kalife ET, Ehdaivand S, et al
    Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4619.
    PubMed     Text format     Abstract available


  821. LI W, Kwok CC, Chan DC, Wang F, et al
    Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4614.
    PubMed     Text format     Abstract available


  822. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4578.
    PubMed     Text format     Abstract available


  823. IBRAHIM MFK, Hilton J, Mazzarello S, Fergusson D, et al
    A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4604.
    PubMed     Text format     Abstract available


  824. WANG J, Fan T, He Y, Chen X, et al
    (99m)Tc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4591.
    PubMed     Text format     Abstract available


  825. PISTILLI B, Pluard T, Urruticoechea A, Farci D, et al
    Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Breast Cancer Res Treat. 2017 Dec 2. pii: 10.1007/s10549-017-4596.
    PubMed     Text format     Abstract available


    November 2017
  826. REINERT T, Debiasi M, Bines J, Barrios CH, et al
    Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4593.
    PubMed     Text format     Abstract available


  827. XIA Z, Baumgartner KB, Baumgartner RN, Boone SD, et al
    Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4600.
    PubMed     Text format     Abstract available


  828. MATIKAS A, Margolin S, Hellstrom M, Johansson H, et al
    Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4599.
    PubMed     Text format     Abstract available


  829. YU YF, Wang Y, Fu TP, Chen K, et al
    Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 29. pii: 10.1007/s10549-017-4592.
    PubMed     Text format     Abstract available


  830. WANG Z, Kong J, Wu Y, Zhang J, et al
    PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4597.
    PubMed     Text format     Abstract available


  831. TRENTHAM-DIETZ A, Ergun MA, Alagoz O, Stout NK, et al
    Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4582.
    PubMed     Text format     Abstract available


  832. LOHRISCH C, Francl M, Sun S, Villa D, et al
    Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.
    Breast Cancer Res Treat. 2017 Nov 27. pii: 10.1007/s10549-017-4586.
    PubMed     Text format     Abstract available


  833. VILLEGAS SL, Darb-Esfahani S, von Minckwitz G, Huober J, et al
    Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2017 Nov 25. pii: 10.1007/s10549-017-4581.
    PubMed     Text format     Abstract available


  834. LIU YL, Connolly EP, Kalinsky K
    Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4590.
    PubMed     Text format    


  835. PEZO RC, Chen TW, Berman HK, Mulligan AM, et al
    Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4580.
    PubMed     Text format     Abstract available


  836. ALTUNDAG K
    Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4589.
    PubMed     Text format    


  837. COLOMER R, Hall P, Szkultecka-Debek M, Bondi RC, et al
    Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
    Breast Cancer Res Treat. 2017 Nov 23. pii: 10.1007/s10549-017-4567.
    PubMed     Text format     Abstract available


  838. LECLERC M, Neuhausen SL, Schayek H, Laitman Y, et al
    Are VNTRs co-localizing with breast cancer-associated SNPs?
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4588.
    PubMed     Text format     Abstract available


  839. DIELI-CONWRIGHT CM, Parmentier JH, Sami N, Lee K, et al
    Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention.
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4576.
    PubMed     Text format     Abstract available


  840. O'SHAUGHNESSY J, Petrakova K, Sonke GS, Conte P, et al
    Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4518.
    PubMed     Text format     Abstract available


  841. NILSSON MP, Torngren T, Henriksson K, Kristoffersson U, et al
    BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4584.
    PubMed     Text format     Abstract available


  842. ASLEH K, Won JR, Gao D, Voduc KD, et al
    Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4583.
    PubMed     Text format     Abstract available


  843. BROUCKAERT O, Van Asten K, Laenen A, Soubry A, et al
    Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4579.
    PubMed     Text format     Abstract available


  844. RIER HN, Jager A, Sleijfer S, van Rosmalen J, et al
    Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 17. doi: 10.1007/s10549-017-4574.
    PubMed     Text format     Abstract available


  845. ABDEL-RAHMAN O
    Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.
    Breast Cancer Res Treat. 2017 Nov 15. doi: 10.1007/s10549-017-4577.
    PubMed     Text format     Abstract available


  846. MIJWEL S, Backman M, Bolam KA, Jervaeus A, et al
    Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4571.
    PubMed     Text format     Abstract available


  847. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Correction to: Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4568.
    PubMed     Text format     Abstract available


  848. MENESES K, Benz R, Bail JR, Vo JB, et al
    Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4564.
    PubMed     Text format     Abstract available


  849. DODSON A, Okonji D, Assersohn L, Rigg A, et al
    Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4514.
    PubMed     Text format     Abstract available


  850. BOSTNER J, Alayev A, Berman AY, Fornander T, et al
    Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4508.
    PubMed     Text format     Abstract available


  851. GILLMAN AS, Gardiner CK, Koljack CE, Bryan AD, et al
    Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4573.
    PubMed     Text format     Abstract available


  852. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Correction to: Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4569.
    PubMed     Text format     Abstract available


  853. KWA M, Li X, Novik Y, Oratz R, et al
    Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4570.
    PubMed     Text format     Abstract available


  854. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4565.
    PubMed     Text format     Abstract available


  855. LYNCE F, Blackburn MJ, Cai L, Wang H, et al
    Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4563.
    PubMed     Text format     Abstract available


  856. SOPIK V, Sun P, Narod SA
    Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4572.
    PubMed     Text format     Abstract available


  857. BRIANESE RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, et al
    BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4552.
    PubMed     Text format     Abstract available


  858. EVANS DG, Harkness EF, Howel S, Woodward ER, et al
    Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4557.
    PubMed     Text format     Abstract available


  859. GOING CC, Alexandrova L, Lau K, Yeh CY, et al
    Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4562.
    PubMed     Text format     Abstract available


  860. MURPHY BL, Zalewski NL, Degnim AC, McKeon A, et al
    Breast cancer-related paraneoplastic neurologic disease.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4566.
    PubMed     Text format     Abstract available


  861. RIMAWI MF, De Angelis C, Contreras A, Pareja F, et al
    Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4533.
    PubMed     Text format     Abstract available


  862. LAMBERT LK, Balneaves LG, Howard AF, Gotay CC, et al
    Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4561.
    PubMed     Text format     Abstract available


  863. KIRKHAM AA, Eves ND, Shave RE, Bland KA, et al
    The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4554.
    PubMed     Text format     Abstract available


  864. FREEDMAN RA, Tolaney SM
    Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Breast Cancer Res Treat. 2017 Nov 4. doi: 10.1007/s10549-017-4560.
    PubMed     Text format     Abstract available


  865. RODRIGUEZ-WALLBERG KA, Eloranta S, Krawiec K, Lissmats A, et al
    Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
    Breast Cancer Res Treat. 2017 Nov 2. doi: 10.1007/s10549-017-4555.
    PubMed     Text format     Abstract available


    October 2017
  866. NGUYEN F, Pena L, Ibisch C, Loussouarn D, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4548.
    PubMed     Text format     Abstract available


  867. RABOW M, Small R, Jow A, Majure M, et al
    The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4556.
    PubMed     Text format     Abstract available


  868. PALMIERI C, Stein RC, Liu X, Hudson E, et al
    Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2017 Oct 25. doi: 10.1007/s10549-017-4539.
    PubMed     Text format     Abstract available


  869. BOCK CH, Jay AM, Dyson G, Beebe-Dimmer JL, et al
    The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.
    Breast Cancer Res Treat. 2017 Oct 24. doi: 10.1007/s10549-017-4521.
    PubMed     Text format     Abstract available


  870. DIRIX LY, Takacs I, Jerusalem G, Nikolinakos P, et al
    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4537.
    PubMed     Text format     Abstract available


  871. ABADIE J, Nguyen F, Loussouarn D, Pena L, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4542.
    PubMed     Text format     Abstract available


  872. ALTUNDAG K
    Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4544.
    PubMed     Text format    


  873. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4541.
    PubMed     Text format     Abstract available


  874. SONKE GS, Hart LL, Campone M, Erdkamp F, et al
    Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Oct 22. doi: 10.1007/s10549-017-4523.
    PubMed     Text format     Abstract available


  875. TAN Q, Qin Q
    Does the elevation of CAMLs predict metastatic breast cancer patients' survival?
    Breast Cancer Res Treat. 2017 Oct 20. doi: 10.1007/s10549-017-4546.
    PubMed     Text format    


  876. MORDANG JJ, Gubern-Merida A, Bria A, Tortorella F, et al
    The importance of early detection of calcifications associated with breast cancer in screening.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4527.
    PubMed     Text format     Abstract available


  877. LUBINSKI J, Marciniak W, Muszynska M, Huzarski T, et al
    Serum selenium levels predict survival after breast cancer.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4525.
    PubMed     Text format     Abstract available


  878. MALMGREN JA, Mayer M, Atwood MK, Kaplan HG, et al
    Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4529.
    PubMed     Text format     Abstract available


  879. SCHON K, Tischkowitz M
    Clinical implications of germline mutations in breast cancer: TP53.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4531.
    PubMed     Text format     Abstract available


  880. FIETZ T, Zahn MO, Kohler A, Engel E, et al
    Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4534.
    PubMed     Text format     Abstract available


  881. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4530.
    PubMed     Text format     Abstract available


  882. BERNSTEIN V, Ellard SL, Dent SF, Tu D, et al
    A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4538.
    PubMed     Text format     Abstract available


  883. ADACHI Y, Yoshimura M, Nishida K, Usuki H, et al
    Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models.
    Breast Cancer Res Treat. 2017 Oct 12. doi: 10.1007/s10549-017-4532.
    PubMed     Text format     Abstract available


  884. ALTUNDAG K
    Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
    Breast Cancer Res Treat. 2017 Oct 11. doi: 10.1007/s10549-017-4536.
    PubMed     Text format    


  885. DOMINICI LS, Sineshaw HM, Jemal A, Lin CC, et al
    Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Breast Cancer Res Treat. 2017 Oct 9. doi: 10.1007/s10549-017-4528.
    PubMed     Text format     Abstract available


  886. PAGE DB, Wen H, Brogi E, Dure D, et al
    Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
    Breast Cancer Res Treat. 2017 Oct 6. doi: 10.1007/s10549-017-4520.
    PubMed     Text format     Abstract available


  887. KAIDAR-PERSON O, Meattini I, Jain P, Bult P, et al
    Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Breast Cancer Res Treat. 2017 Oct 3. doi: 10.1007/s10549-017-4526.
    PubMed     Text format     Abstract available


    September 2017
  888. XIA J, Tang Z, Deng Q, Yang R, et al
    Predictors of the quality of life in Chinese breast cancer survivors.
    Breast Cancer Res Treat. 2017 Sep 30. doi: 10.1007/s10549-017-4512.
    PubMed     Text format     Abstract available


  889. GALLARDO A, Lerma E
    Response letter to: Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4524.
    PubMed     Text format    


  890. ALTUNDAG K
    Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4515.
    PubMed     Text format    


  891. LUU T, Kim KP, Blanchard S, Anyang B, et al
    Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4516.
    PubMed     Text format     Abstract available


  892. TSOUTSOU PG, Durham AD, Vozenin MC
    A need for biology-driven personalized radiotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4522.
    PubMed     Text format    


  893. SAYED S, Moloo Z, Wasike R, Bird P, et al
    Ethnicity and breast cancer characteristics in Kenya.
    Breast Cancer Res Treat. 2017 Sep 26. doi: 10.1007/s10549-017-4511.
    PubMed     Text format     Abstract available


  894. LIU YL, Saraf A, Catanese B, Lee SM, et al
    Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4507.
    PubMed     Text format     Abstract available


  895. CRONIN-FENTON D, Kjaersgaard A, Norgaard M, Amelio J, et al
    Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4510.
    PubMed     Text format     Abstract available


  896. KAUFMAN DI, Shah C, Vicini FA, Rizzi M, et al
    Erratum to: Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Sep 20. doi: 10.1007/s10549-017-4505.
    PubMed     Text format     Abstract available


  897. RICE BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, et al
    Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat. 2017 Sep 18. doi: 10.1007/s10549-017-4506.
    PubMed     Text format     Abstract available


  898. JEONG IJ, Lee SG, Kim YH, Ko BS, et al
    Characteristics and prognosis of breast cancer after liver or kidney transplantation.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4504.
    PubMed     Text format     Abstract available


  899. GIANNAKEAS V, Narod SA
    The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4476.
    PubMed     Text format     Abstract available


  900. LEON-FERRE RA, Polley MY, Liu H, Gilbert JA, et al
    Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4499.
    PubMed     Text format     Abstract available


  901. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4501.
    PubMed     Text format     Abstract available


  902. SIEGELMANN-DANIELI N, Katzir I, Landes JV, Segal Y, et al
    Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4491.
    PubMed     Text format     Abstract available


  903. KOCHI M, Iwamoto T, Niikura N, Bianchini G, et al
    Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4502.
    PubMed     Text format     Abstract available


  904. MASUNAGA N, Kagara N, Motooka D, Nakamura S, et al
    Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4487.
    PubMed     Text format     Abstract available


  905. ROCQUE GB, Williams CP, Jones MI, Kenzik KM, et al
    Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.
    Breast Cancer Res Treat. 2017 Sep 12. doi: 10.1007/s10549-017-4498.
    PubMed     Text format     Abstract available


  906. NIIKURA N, Shimomura A, Fukatsu Y, Sawaki M, et al
    Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4489.
    PubMed     Text format     Abstract available


  907. GREGOROWITSCH ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, et al
    Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4495.
    PubMed     Text format     Abstract available


  908. SAUNUS JM, Smart CE, Kutasovic JR, Johnston RL, et al
    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res Treat. 2017 Sep 9. doi: 10.1007/s10549-017-4496.
    PubMed     Text format     Abstract available


    August 2017
  909. WEBER WP, Soysal SD, El-Tamer M, Sacchini V, et al
    First international consensus conference on standardization of oncoplastic breast conserving surgery.
    Breast Cancer Res Treat. 2017;165:139-149.
    PubMed     Text format     Abstract available


  910. CONT NT, Maggiorotto F, Martincich L, Rivolin A, et al
    Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy.
    Breast Cancer Res Treat. 2017;165:85-95.
    PubMed     Text format     Abstract available


    June 2017
  911. SANTEN RJ, Radisky DC, Degnim A, Frost MH, et al
    Aromatase expression in atypical ductal hyperplasia in women.
    Breast Cancer Res Treat. 2017;163:623-629.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: